1
|
Lee JS, Batchelder AW, Stanton AM, Westphal L, Klevens RM, Mayer KH, O'Cleirigh C. Structural vulnerabilities and PrEP awareness among Boston heterosexuals and people who inject drugs at risk for HIV: findings from 2018 to 2019 cycles from the Boston, MA site of the NHBS. AIDS Care 2024; 36:641-651. [PMID: 38091449 PMCID: PMC10994762 DOI: 10.1080/09540121.2023.2288646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 11/21/2023] [Indexed: 04/05/2024]
Abstract
Little is known about biopsychosocial factors relating to pre-exposure prophylaxis (PrEP) awareness among people with either heterosexual or injection drug use HIV risk behaviors. Participants engaged in vaginal/anal sex with a person of the opposite sex (N = 515) or were people who injected drugs (PWID; N = 451) in the past 12 months from 2018-2019 in Boston, MA. We examined associations between PrEP awareness and: homelessness; perceived HIV-related stigma; country of birth; bacterial STDs, chlamydia, and/or gonorrhea in the past 12 months, lifetime hepatitis C virus (HCV) infection, sexual orientation, and poverty. More PWID (36.8%) were aware of PrEP than people with heterosexual HIV risk (28%; p = .001). Among people with heterosexual risk, homelessness (aOR = 1.99, p = .003), and among PWID: homelessness (aOR = 2.11, p = .032); bacterial STD (aOR = 2.96, p = .012); chlamydia (aOR = 6.14, p = .008); and HCV (aOR = 2.40, p < .001) were associated with increased likelihood of PrEP awareness. In the combined sample: homelessness (aOR = 2.25, p < .001); HCV (aOR = 2.18, p < .001); identifying as homosexual (aOR = 3.71, p = .036); and bisexual (aOR = 1.55, p = .016) were each associated with PrEP awareness. Although having an STD, HCV, identifying as homosexual or bisexual, and experiencing homelessness were associated with increased PrEP awareness, most participants were unaware of PrEP. Efforts to increase PrEP awareness could engage PWID and heterosexual HIV risk behavior.
Collapse
Affiliation(s)
- J S Lee
- The Fenway Institute, Fenway Health, Boston, MA, USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - A W Batchelder
- The Fenway Institute, Fenway Health, Boston, MA, USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - A M Stanton
- The Fenway Institute, Fenway Health, Boston, MA, USA
- Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA
| | - L Westphal
- The Fenway Institute, Fenway Health, Boston, MA, USA
| | - R M Klevens
- Massachusetts Department of Public Health, Bureau of Infectious Disease and Laboratory Sciences, Boston, MA, USA
| | - K H Mayer
- The Fenway Institute, Fenway Health, Boston, MA, USA
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - C O'Cleirigh
- The Fenway Institute, Fenway Health, Boston, MA, USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| |
Collapse
|
2
|
Salari K, Lee JS, Ye H, Seymour ZA, Lee KC, Chinnaiyan P, Grills IS. Long-term survival in patients with brain-only metastatic non-small cell lung cancer undergoing upfront intracranial stereotactic radiosurgery and definitive treatment to the thoracic primary site. Radiother Oncol 2024; 196:110262. [PMID: 38556172 DOI: 10.1016/j.radonc.2024.110262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 03/21/2024] [Accepted: 03/24/2024] [Indexed: 04/02/2024]
Abstract
BACKGROUND AND PURPOSE To evaluate modern clinical outcomes for patients with brain-only metastatic non-small cell lung cancer (NSCLC) treated with intracranial stereotactic radiosurgery (SRS) with or without definitive treatment of the primary site. MATERIALS AND METHODS Patients with synchronously diagnosed NSCLC and brain-only metastatic disease treated with intracranial SRS at a single institution were retrospectively identified. Patients were stratified based on whether they did (A) or did not (B) receive definitive primary site treatment. Patient characteristics and clinical outcomes were compared. RESULTS From 2008 to 2022, 103 patients were identified, 53 of whom received definitive primary site treatment. Median follow-up was 2.1 y (A) and 0.8 y (B) (p < 0.001). 28 (53 %) patients in Group A received immune checkpoint inhibitor (ICI) therapy versus 19 (38 %) in Group B (p = 0.13) and there were no other statistically significant baseline or treatment characteristic differences between the groups. 5-year local-PFS was 34.5 % (A) versus 0 % (B) (p < 0.001). 5-year regional-PFS was 33.0 % (A) versus 0 % (B) (p < 0.001). 5-year distant body-PFS was 34.0 % (A) versus 0 % (B) (p < 0.001). 5-year CNS-PFS was 14.7 % (A) versus 0 % (B) (p = 0.12). 5-year OS was 40.2 % (A) versus 0 % (B) (p = 0.001). 5-year CSS was 67.6 % (A) versus 0 % (B) (p = 0.002). On multivariable analysis, lack of definitive treatment to the primary site (HR = 2.40), AJCC T3-4 disease (HR = 2.73), and lack of ICI therapy (HR = 2.86) were significant predictors of death. CONCLUSION Definitive treatment to the thoracic primary site in patients with brain-only metastatic NSCLC after intracranial radiosurgery was associated with slower progression of disease and improved survival.
Collapse
Affiliation(s)
- K Salari
- Department of Radiation Oncology, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, United States.
| | - J S Lee
- Department of Radiation Oncology, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, United States
| | - H Ye
- Department of Radiation Oncology, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, United States
| | - Z A Seymour
- Department of Radiation Oncology, Corewell Health Dearborn Hospital, Dearborn, MI, United States
| | - K C Lee
- Department of Radiation Oncology, Corewell Health Troy Hospital, Troy, MI, United States
| | - P Chinnaiyan
- Department of Radiation Oncology, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, United States
| | - I S Grills
- Department of Radiation Oncology, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, United States
| |
Collapse
|
3
|
Lee JS, Mallitt K, Fischer G, Saunderson RB. An individual patient data meta-analysis of wound care in patients with toxic epidermal necrolysis. Australas J Dermatol 2024; 65:128-142. [PMID: 38063272 DOI: 10.1111/ajd.14193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 10/20/2023] [Accepted: 11/19/2023] [Indexed: 03/10/2024]
Abstract
Toxic epidermal necrolysis (TEN) involves extensive mucocutaneous loss, and care is supportive. The approach to wound care includes surgical debridement or using dressings while leaving the epidermis intact. Robust evidence for either approach is lacking. We compared surgical debridement to the use of dressings while leaving the epidermis in situ (referred to hereon as dressings) in adult patients with TEN. The primary outcome assessed was mortality. The secondary outcome was time to re-epithelialisation. The impact of medications was evaluated. An individual patient data (IPD) systematic review and meta-analysis was undertaken. A random effects meta-analysis and survival analysis for IPD data examined mortality, re-epithelisation time and the effect of systemic medications. The quality of evidence was rated per the Grading of Recommendations Assessment, Development and Evaluation (GRADE). PROSPERO: CRD42021266611 Fifty-four studies involving 227 patients were included in the systematic review and meta-analysis, with a GRADE from very low to moderate. There was no difference in survival in patients who had surgical debridement or dressings (univariate: p = 0.91, multivariate: p = 0.31). Patients who received dressings re-epithelialised faster than patients who underwent debridement (multivariate HR: 1.96 [1.09-3.51], p = 0.023). Intravenous immunoglobulin (univariate HR: 0.21 [0.09-0.45], p < 0.001; multivariate HR: 0.22 [0.09-0.53], p < 0.001) and cyclosporin significantly reduced mortality (univariate HR: 0.09 [0.01-0.96], p = 0.046; multivariate HR: 0.06 [0.01-0.73], p = 0.028) irrespective of the wound care. This study supports the expert consensus of the dermatology hospitalists, that wound care in patients with TEN should be supportive with the epidermis left intact and supported with dressings, which leads to faster re-epithelialisation.
Collapse
Affiliation(s)
- J S Lee
- The University of Notre Dame, Darlinghurst, New South Wales, Australia
| | - K Mallitt
- Sydney School of Public Health, Faculty of Medicine, University of Sydney, Camperdown, New South Wales, Australia
- School of Psychiatry, Faculty of Medicine, UNSW Sydney, Kensington, New South Wales, Australia
| | - G Fischer
- Northern Clinical School, University of Sydney, St Leonards, New South Wales, Australia
- Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
| | - R B Saunderson
- Northern Clinical School, University of Sydney, St Leonards, New South Wales, Australia
- Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
| |
Collapse
|
4
|
Lee JS, Dilworth JT. Proton Re-Irradiation with Concurrent Hyperthermia in Patients with Recurrent Breast Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e190. [PMID: 37784824 DOI: 10.1016/j.ijrobp.2023.06.1053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The aim of this study is to evaluate the safety and effectiveness of proton re-irradiation with concurrent hyperthermia in the treatment of recurrent breast cancer. MATERIALS/METHODS We retrospectively identified patients previously treated with photon whole breast or chest wall irradiation for a primary breast cancer at our institution, who subsequently developed a histologically-confirmed locoregional recurrence or new ipsilateral primary breast cancer and underwent proton chest wall re-irradiation with concurrent hyperthermia as part of definitive treatment. Acute toxicity was evaluated once weekly while on-treatment and at 2 weeks and 3 months post-treatment. Toxicities were graded according to CTCAE v4.0. RESULTS Fifteen patients received proton re-irradiation with concurrent superficial hyperthermia at our institution from August 2018 to December 2022. Median interval between radiation treatment courses was 7.7 years (range 1-30 years). Four patients (26%) had gross, unresected disease at the time of re-treatment. The median initial radiation dose, re-irradiation dose, and cumulative EQD2 was 60.4 Gy (50.6-61.2 Gy), 60 Gy (RBE) (45-66 Gy (RBE)), and 120 Gy (RBE) (103-126 Gy (RBE)), respectively. Patients received a median of 9 (3-14) concurrent hyperthermia treatments delivered twice weekly, and 13 patients (87%) received seven or more hyperthermia treatments. Median toxicity follow-up was 9 months (0-36 months). Acute grade 3 toxicities included two patients (13%) with grade 3 dermatitis, both of which resolved with conservative management within 3 months of treatment completion. Chronic grade 2 or higher toxicities included two grade 2 hyperpigmentation, one grade 3 induration, one grade 2 telangiectasia, and one grade 2 rib fracture. There were no grade 4-5 acute or late toxicities. There was one in-field local recurrence and one regional recurrence outside of the re-irradiation field. Both patients had gross, unresected disease at the time of re-irradiation. Two patients (13%) developed distant disease. CONCLUSION Proton re-irradiation with concurrent hyperthermia is feasible and well-tolerated in the re-treatment of breast cancer. Further studies are warranted to determine long-term toxicity and oncologic outcomes.
Collapse
Affiliation(s)
- J S Lee
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - J T Dilworth
- Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI
| |
Collapse
|
5
|
Lee JS, Lowell JL, Whitewater K, Roane TM, Miller CS, Chan AP, Sylvester AW, Jackson D, Hunter LE. Monitoring environmental microbiomes: Alignment of microbiology and computational biology competencies within a culturally integrated curriculum and research framework. Mol Ecol Resour 2023. [PMID: 37702134 DOI: 10.1111/1755-0998.13867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 08/18/2023] [Accepted: 08/30/2023] [Indexed: 09/14/2023]
Abstract
We have developed a flexible undergraduate curriculum that leverages the place-based research of environmental microbiomes to increase the number of Indigenous researchers in microbiology, data science and scientific computing. Monitoring Environmental Microbiomes (MEM) provides a curriculum and research framework designed to integrate an Indigenous approach when conducting authentic scientific research and to build interest and confidence at the undergraduate level. MEM has been successfully implemented as a short summer workshop to introduce computing practices in microbiome analysis. Based on self-assessed student knowledge of topics and skills, increased scientific confidence and interest in genomics careers were observed. We propose MEM be incorporated in a scalable course-based research experience for undergraduate institutions, including tribal colleges and universities, community colleges and other minority serving institutions. This coupled curricular and research framework explicitly considers cultural perspectives, access and equity to train a diverse future workforce that is more informed to engage in microbiome research and to translate microbiome science to benefit community and environmental health.
Collapse
Affiliation(s)
- J S Lee
- Department of Chemistry and Biochemistry, Fort Lewis College, Durango, Colorado, USA
| | - J L Lowell
- Department of Public Health, Fort Lewis College, Durango, Colorado, USA
| | - K Whitewater
- Department of Chemistry and Biochemistry, Fort Lewis College, Durango, Colorado, USA
| | - T M Roane
- Department of Integrative Biology, University of Colorado Denver, Denver, Colorado, USA
| | - C S Miller
- Department of Integrative Biology, University of Colorado Denver, Denver, Colorado, USA
| | - A P Chan
- J. Craig Venter Institute, Rockville, Maryland, USA
| | - A W Sylvester
- Marine Biological Laboratory, Woods Hole, Massachusetts, USA
- University of Wyoming, Laramie, Wyoming, USA
| | - D Jackson
- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA
| | - L E Hunter
- Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| |
Collapse
|
6
|
Knisz J, Eckert R, Gieg LM, Koerdt A, Lee JS, Silva ER, Skovhus TL, An Stepec BA, Wade SA. Microbiologically influenced corrosion-more than just microorganisms. FEMS Microbiol Rev 2023; 47:fuad041. [PMID: 37437902 PMCID: PMC10479746 DOI: 10.1093/femsre/fuad041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 06/29/2023] [Accepted: 07/11/2023] [Indexed: 07/14/2023] Open
Abstract
Microbiologically influenced corrosion (MIC) is a phenomenon of increasing concern that affects various materials and sectors of society. MIC describes the effects, often negative, that a material can experience due to the presence of microorganisms. Unfortunately, although several research groups and industrial actors worldwide have already addressed MIC, discussions are fragmented, while information sharing and willingness to reach out to other disciplines are limited. A truly interdisciplinary approach, which would be logical for this material/biology/chemistry-related challenge, is rarely taken. In this review, we highlight critical non-biological aspects of MIC that can sometimes be overlooked by microbiologists working on MIC but are highly relevant for an overall understanding of this phenomenon. Here, we identify gaps, methods, and approaches to help solve MIC-related challenges, with an emphasis on the MIC of metals. We also discuss the application of existing tools and approaches for managing MIC and propose ideas to promote an improved understanding of MIC. Furthermore, we highlight areas where the insights and expertise of microbiologists are needed to help progress this field.
Collapse
Affiliation(s)
- J Knisz
- Department of Water Supply and Sewerage, Faculty of Water Sciences, University of Public Service, 6500, Baja, Hungary
| | - R Eckert
- Microbial Corrosion Consulting, LLC, Commerce Township, 48382, MI, USA
| | - L M Gieg
- Petroleum Microbiology Research Group, Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, Alberta T2N 1N4, Canada
| | - A Koerdt
- Federal Institute for Materials Research and Testing (BAM), 12205, Berlin, Germany
| | - J S Lee
- Naval Research Laboratory, Ocean Sciences Division, Stennis Space Center, 39529, MS, USA
| | - E R Silva
- BioISI—Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8 bdg, 1749-016, Lisboa, Portugal
- CERENA - Centre for Natural Resources and the Environment, Instituto Superior Técnico, University of Lisbon, Av. Rovisco Pais, 1, 1049-001, Lisboa, Portugal
| | - T L Skovhus
- Research Center for Built Environment, Energy, Water and Climate, VIA, University College, 8700, Horsens, Denmark
| | - B A An Stepec
- Department of Energy and Technology, NORCE Norwegian Research Centre AS, Nygårdsgaten 112, 5008 Bergen, Norway
| | - S A Wade
- Bioengineering Research Group, Swinburne University of Technology, 3122, Melbourne, Australia
| |
Collapse
|
7
|
Abstract
BACKGROUND Healthcare workers (HCWs) with latent tuberculosis infection (LTBI) have a high risk of active tuberculosis and need systematic LTBI screening and treatment. However, acceptance and adherence rates of LTBI treatment are low. AIMS To examine the specific reasons for the loss at each LTBI treatment-cascade stage: acceptance, continuation and completion of LTBI treatment in HCWs. METHODS This retrospective descriptive study was conducted among 61 HCWs with an interferon-gamma release assay-confirmed LTBI diagnosis who were prescribed LTBI treatment at a tertiary hospital in the Republic of Korea. Data were analysed using Pearson's chi-square, Fisher's exact, independent t-test and Mann-Whitney U-test. A word cloud analysis was used to describe the perceived meaning of LTBI in HCWs. RESULTS HCWs who refused or discontinued LTBI treatment perceived LTBI as 'not a big deal', whereas HCWs who completed LTBI treatment had a high-risk perception of the LTBI prognosis, such as 'frightened about adverse prognosis'. Determinants of non-adherence to the recommended LTBI treatment included a busy work schedule, side effects of anti-tuberculosis agents and the inconvenience of regularly taking anti-tuberculosis agents. CONCLUSIONS To ensure LTBI treatment adherence in HCWs, effective interventions that are customized to each stage of the LTBI treatment should be developed, with due consideration of the stage-specific perceived facilitators and barriers in the LTBI treatment cascade.
Collapse
Affiliation(s)
- H Yang
- Chonnam National University, College of Nursing, Gwangju 61469, Republic of Korea
| | - J S Lee
- Chonnam National University Hwasun Hospital, Hwasun 58128, Republic of Korea
| | - Y Kim
- Chonnam National University, College of Nursing, Gwangju 61469, Republic of Korea
| |
Collapse
|
8
|
Oh CR, Kim JE, Lee JS, Kim SY, Kim TW, Choi J, Kim J, Park IJ, Lim SB, Park JH, Kim JH, Choi MK, Cha Y, Baek JY, Beom SH, Hong YS. Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O 6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02. Clin Oncol (R Coll Radiol) 2023; 35:e143-e152. [PMID: 36376167 DOI: 10.1016/j.clon.2022.10.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 09/03/2022] [Accepted: 10/20/2022] [Indexed: 11/13/2022]
Abstract
AIMS To evaluate the clinical efficacy of adding temozolomide (TMZ) to preoperative capecitabine (CAP)-based chemoradiotherapy in patients with locally advanced rectal cancer (LARC) and validate O6-methylguanine DNA methyltransferase (MGMT) methylation status as a predictive marker for TMZ combined regimens. MATERIALS AND METHODS LARC patients with clinical stage II (cT3-4N0) or III (cTanyN+) disease were enrolled. They were stratified into unmethylated MGMT (uMGMT) and methylated MGMT (mMGMT) groups by methylation-specific polymerase chain reaction before randomisation and were then randomly assigned (1:1) to one of four treatment arms: uMGMT/CAP (arm A), uMGMT/TMZ + CAP (arm B), mMGMT/CAP (arm C) and mMGMT/TMZ + CAP (arm D). The primary end point was the pathological complete response (pCR) rate. RESULTS Between November 2017 and July 2020, 64 patients were randomised. Slow accrual caused early study termination. After excluding four ineligible patients, 60 were included in the full analysis set. The pCR rate was 15.0% (9/60), 0%, 14.3%, 18.8% and 26.7% for the entire cohort, arms A, B, C and D, respectively (P = 0.0498 between arms A and D). The pCR rate was 9.7% in the CAP group (arms A + C), 20.7% in the TMZ + CAP group (arms B + D), 6.9% in the uMGMT group (arms A + B) and 22.6% in the mMGMT group (arms C + D). Grade 1-2 nausea or vomiting was significantly more frequent in the TMZ + CAP treatment groups (arms B + D) than in the CAP treatment groups (arms A + C, P < 0.001) with no difference in grade 3 adverse events. There were no grade 4 or 5 adverse events. CONCLUSION The addition of TMZ to CAP-based chemoradiotherapy tended to improve pCR rates, particularly in those with mMGMT LARC. MGMT status may warrant further investigation as a predictive biomarker for chemotherapeutic agents and radiotherapy.
Collapse
Affiliation(s)
- C R Oh
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea
| | - J E Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - J S Lee
- Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - S Y Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - T W Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - J Choi
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - J Kim
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - I J Park
- Department of Colon and Rectal Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - S-B Lim
- Department of Colon and Rectal Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - J-H Park
- Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - J H Kim
- Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - M K Choi
- Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea
| | - Y Cha
- Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea
| | - J Y Baek
- Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea
| | - S-H Beom
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Y S Hong
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
| |
Collapse
|
9
|
Pitt B, Bhatt DL, Schotzinger RJ, Pacyniak E, Jowett J, Lee JS. A safety and pharmacodynamic study of the highly selective aldosterone synthase inhibitor PB6440 in the cynomolgus monkey. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.3061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Aldosterone is an important mediator of hypertension, particularly resistant hypertension, heart failure, and chronic kidney disease. PB6440 is a potent inhibitor of aldosterone synthase (CYP11B2) with high selectivity over the closely related enzyme CYP11B1. In previous studies in cynomolgus monkeys, PB6440 exhibited excellent oral bioavailability and a marked suppression of aldosterone synthesis at doses as low as 1 mg/kg/day. Importantly, no effect was observed on cortisol production nor significant changes noted in plasma concentrations of the steroid precursors 11-deoxycortisol or deoxycorticosterone (DOC), which are dependent on CYP11B1 activity. The purpose of the current study was to assess the safety and pharmacodynamics of higher doses of PB6440 in the cynomolgus monkey in order to determine a therapeutic index prior to initiation of studies in humans.
Methods
Male and female cynomolgus monkeys (2/sex/dose group) were administered 0, 10, 30 or 100 mg/kg PB6440 once-daily for 14 days by oral gavage. Assessment of safety was based on mortality, clinical observations, body weights, and clinical and anatomic pathology. Blood samples were also collected for pharmacodynamic analysis, including aldosterone, cortisol, 11-deoxycortisol, DOC, and ACTH.
Results
PB6440 was well tolerated at all doses. There were no deaths and no reports of clinical observations at any dose level. Mild decreases in body weight were observed in PB6440-treated animals, which were likely due to the diuretic effects of the compound. PB6440 caused an increase in adrenal weights which was associated with hypertrophy of the adrenal zona fasciculata, a finding which has previously been observed with other aldosterone synthase inhibitors. PB6440 led to marked declines in basal aldosterone levels of −97%, −97% and −98% from baseline at 10, 30 and 100 mg/kg/day, respectively, at 24-hours following the final dose. Despite these clear declines in circulating aldosterone levels, no meaningful changes in cortisol, 11-deoxycortisol, DOC, or ACTH levels were observed, supporting lack of CYP11B1 inhibition. PB6440 led to expected decreases in plasma sodium (up to 7 nmol/L at the high dose). No effect on plasma potassium levels were observed at any dose level.
Conclusions
PB6440 was well tolerated in the cynomolgus monkey at doses that are much higher than needed for potent aldosterone suppression based on previous studies. At the highest dose level tested (100 mg/kg), which led to a 98% reduction in basal aldosterone levels, no evidence of significant CYP11B1 inhibition was observed. The absence of an increase in plasma potassium in the presence of a plasma sodium decline merits further study. Thus, PB6440 is a highly selective novel aldosterone synthase inhibitor for the potential treatment of hypertension, heart failure, and chronic kidney disease in humans.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): PhaseBio Pharmaceuticals Inc.
Collapse
Affiliation(s)
- B Pitt
- University of Michigan School of Medicine , Ann Arbor , United States of America
| | - D L Bhatt
- Brigham and Women'S Hospital, Harvard Medical School , Boston , United States of America
| | | | - E Pacyniak
- Selenity Therapeutics , Durham , United States of America
| | - J Jowett
- PhaseBio Pharmaceuticals Inc. , Malvern , United States of America
| | - J S Lee
- PhaseBio Pharmaceuticals Inc. , Malvern , United States of America
| |
Collapse
|
10
|
Cho EJ, Kang MR, Kim JH, Lee JI, Son ES, Park CH, Aung WW, Lee JS. Evaluation of the MolecuTech ® REBA MTB-XMDR kit for detection of pre-extensively drug-resistant TB. Int J Tuberc Lung Dis 2022; 26:869-874. [PMID: 35996285 DOI: 10.5588/ijtld.21.0606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND: Rapid diagnosis of drug-resistant TB is critical for early initiation of effective therapy. YD Diagnostics in South Korea recently developed the MolecuTech® REBA MTB-XMDR test to rapidly detect multidrug-resistant TB (MDR-TB), pre-extensively drug-resistant TB (pre-XDR-TB) and resistance to second-line injectable drugs (SLIDs) simultaneously using a fully automated test platform. This study aimed to evaluate the MolecuTech® test for the detection of MDR- and pre-XDR-TB, as well as SLID resistance.METHODS: A total of 151 clinical Mycobacterium tuberculosis isolates from South Korea were tested using the MolecuTech test, and the results were analysed by comparing these with phenotypic drug susceptibility testing (pDST) and sequencing.RESULTS: Compared to pDST, the MolecuTech test showed a sensitivity and specificity of respectively 97.7% and 100.0% for rifampicin (RIF), 82.4% and 100.0% for isoniazid (INH), 97.5% and 97.2% for fluoroquinolones (FQs), and 94.0% and 98.8% for SLIDs. Concordances with the sequencing results of each resistance determinant were 99.3% for RIF, 96.7% for INH, 98.7% for FQs and 99.3% for SLIDs.CONCLUSION: The MolecuTech test is an efficient and reliable rapid molecular diagnostic tool for the simultaneous screening of MDR- and pre-XDR-TB.
Collapse
Affiliation(s)
- E J Cho
- International Tuberculosis Research Center, Gyeongsangnam-do, College of Health Sciences, Catholic University of Pusan, Busan, Republic of Korea
| | - M R Kang
- YD Diagnostics, Gyeonggi-do, College of Health Sciences, Catholic University of Pusan, Busan, Republic of Korea
| | - J H Kim
- YD Diagnostics, Gyeonggi-do, College of Health Sciences, Catholic University of Pusan, Busan, Republic of Korea, Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan, Republic of Korea
| | - J I Lee
- International Tuberculosis Research Center, Gyeongsangnam-do, College of Health Sciences, Catholic University of Pusan, Busan, Republic of Korea
| | - E S Son
- International Tuberculosis Research Center, Gyeongsangnam-do, College of Health Sciences, Catholic University of Pusan, Busan, Republic of Korea
| | - C H Park
- YD Diagnostics, Gyeonggi-do, College of Health Sciences, Catholic University of Pusan, Busan, Republic of Korea, College of Pharmacy, Dongguk University, Seoul, Republic of Korea
| | - W W Aung
- Advanced Molecular Research Centre, Department of Medical Research, Yangon, Myanmar
| | - J S Lee
- International Tuberculosis Research Center, Gyeongsangnam-do, College of Health Sciences, Catholic University of Pusan, Busan, Republic of Korea
| |
Collapse
|
11
|
Han M, Choi JW, Jung WS, Lee JS. Isolated posterior inferior cerebellar artery dissection with ischaemic stroke: evaluating the radiological features and diagnostic feasibility of high-resolution vessel wall imaging. Clin Radiol 2022; 77:584-591. [PMID: 35676104 DOI: 10.1016/j.crad.2022.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 05/06/2022] [Indexed: 11/29/2022]
Abstract
AIM To evaluate the radiological features of isolated posterior inferior cerebellar artery dissection (PICAD) and the feasibility of using high-resolution vessel-wall imaging (HR-VWI) for diagnosing PICAD. MATERIALS AND METHODS Three hundred and nine patients with arterial dissection involving the posterior cerebral circulation, who underwent HR-VWI between March 2012 and July 2019 were reviewed retrospectively. Among them, 44 patients (14.2%) were diagnosed with isolated PICAD in consensus among a neuroradiologist, a neurointerventionist, and a neurologist. Two neuroradiologists reviewed the vessel wall images independently for evidence of dissection (dissection flap, outer diameter enlargement on T2-weighted imaging [WI], mural haematoma). Diagnostic confidence was also scored on a five-point scale. Intra- and interobserver agreement for diagnosing PICAD and detecting evidence of dissection were evaluated. RESULTS Dissection flaps were seen on T2WI in all cases (100%) and on contrast-enhanced T1WI in 34 patients (79.1%). Outer diameter enlargement of the steno-occlusive lesions on angiography was detected in most cases (97.7%). A mural haematoma was detected on three-dimensional (3D) contrast-enhanced motion-sensitised driven-equilibrium T1WI in 97.1% of the cases. The mean diagnostic confidence score derived by two neuroradiologists was 4.72. The two reviewers showed substantial to almost perfect agreement (weighted kappa coefficient: 0.62-0.97). CONCLUSION Use of HR-VWI as a diagnostic tool for PICAD is feasible, and a dissection flap with outer wall enlargement on HR-T2WI allows confident dissection diagnosis. The present data suggest that PICAD might be considered as a stroke aetiology in patients with unexplained ischaemic stroke in the PICA territory, and that PICA evaluation with HR-VWI is both necessary and feasible.
Collapse
Affiliation(s)
- M Han
- Department of Radiology, Ajou University School of Medicine, Ajou University Hospital, Suwon, Republic of Korea; Department of Radiology, Graduate School of Kangwon National University, Chuncheon, Republic of Korea
| | - J W Choi
- Department of Radiology, Ajou University School of Medicine, Ajou University Hospital, Suwon, Republic of Korea.
| | - W S Jung
- Department of Radiology, Ajou University School of Medicine, Ajou University Hospital, Suwon, Republic of Korea; Department of Radiology, Graduate School of Kangwon National University, Chuncheon, Republic of Korea
| | - J S Lee
- Department of Neurology, Ajou University School of Medicine, Ajou University Hospital, Suwon, Republic of Korea
| |
Collapse
|
12
|
Kim MJ, Lee KH, Lee JS, Kim N, Song JY, Shin YH, Yang JM, Lee SW, Hwang J, Rhee SY, Yon DK, Shin JI, Choi YJ. Trends in body mass index changes among Korean adolescents between 2005-2020, including the COVID-19 pandemic period: a national representative survey of one million adolescents. Eur Rev Med Pharmacol Sci 2022; 26:4082-4091. [PMID: 35731079 DOI: 10.26355/eurrev_202206_28978] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
OBJECTIVE The impact of the coronavirus disease 2019 (COVID-19) pandemic on weight gain in children and adolescents remains unknown. We aimed to identify an estimated 15-year trend in mean body mass index (BMI) changes and prevalence of obesity and overweight among Korean adolescents from 2005 to 2020, including the period of the COVID-19 pandemic. PATIENTS AND METHODS We analyzed data taken from a nationwide survey (Korea Youth Risk Behavior Survey), between 2005 and 2020. Representative samples of one million Korean adolescents aged 13-18 years (n=1,057,885) were examined. The 15-year trends in mean BMI and proportion of obesity or overweight, and the changes due to the COVID-19 pandemic were analyzed. RESULTS The data of 1,057,885 Korean adolescents were analyzed (mean age: 14.98 years; females, 48.4%). The estimated weighted mean BMI was 20.5 kg/m2 [95% confidence interval (CI), 20.4-20.5] from 2005 to 2008 and 21.5 kg/m2 (95% CI, 21.4-21.6) in 2020 (during the COVID-19 pandemic). Although the 15-year trend of mean BMI gradually increased, the change in mean BMI before and during the pandemic significantly lessened (βdiff, -0.027; 95% CI, -0.028 to -0.026). The 15-year (2005-2020) trend changes in the prevalence of obesity and overweight were similar (obesity prevalence from 2005-2008, 3.2%; 95% CI, 3.1-3.3 vs. obesity prevalence in 2020, 8.6%; 95% CI, 8.2-9.0; βdiff, -0.309; 95% CI, -0.330 to -0.288). CONCLUSIONS The 15-year trend of overall mean BMI and obesity and overweight prevalence demonstrated a significant increase; however, its slope decreased during the pandemic. These landmark results suggest the need for the development of precise strategies to prevent pediatric obesity and overweight during the COVID-19 pandemic.
Collapse
Affiliation(s)
- M J Kim
- Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Chang SH, Lee JS, Chae JJ, Choe JY, Lee EY. POS0436 EFFECT OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON LUNG MICROENVIRONMENT IN RHEUMATOID ARTHRITIS-ASSOCIATED LUNG DISEASE ANIMAL MODELS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundRheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the pivotal extrapulmonary conditions. However, the pathophysiology of RA-ILD, including the effect of disease-modifying anti-rheumatoid drugs (DMARDs) is largely unknown.ObjectivesTo study the effect of methotrexate and TNFα inhibitor on lung microenvironment of SKG mice using single-nucleus RNA sequencing.MethodsAt age eight to ten weeks, male SKG mice received a single intraperitoneal zymosan A (ZyA) injection to induce arthritis and pneumonitis. We gave them twice-weekly intraperitoneal injections of PBS, methotrexate (7.5 mg/kg; MilliporeSigma), or TNFα inhibitor (100 μg/kg; R&D Systems, Inc., Minneapolis, MN, USA). Nuclei were prepared from frozen lung tissue under ribonuclease-free conditions by a method adapted from an existing protocol.ResultsMacroscopically, pneumonitis was most evident in SKG mice with ZyA and methotrexate treatment; multiple inflammatory cell aggregations were observed. In mice with ZyA and TNFα inhibitor, there were a few perivascular inflammatory cell aggregations as in the mice with ZyA and PBS, compared with the mice without ZyA. A total of 59,860 nuclei were obtained from sixteen mice, four mice from each of the four groups. We classified each cell type using previous reports on the single-nucleus cells of mouse lungs. The most frequently observed cell was the type 2 alveolar (AT2) cell among all four groups. Alveolar epithelial cells were further subclustered into six clusters (Figure 1). Cluster 2 highly expressed type 1 alveolar (AT1) cell marker genes. In mice without ZyA, cluster 0 predominated relative to cluster 1. This proportion was inverted in mice with the ZyA injection, where cluster 1 predominated. TNFα inhibitor treatment reversed the proportion, with cluster 0 predominating in this group. On the other hand, methotrexate treatment further accentuated the predominance of cluster 1 over cluster 0. Interestingly, a distinct cluster 3 was observed after methotrexate treatment. This distinctive alveolar epithelial cell cluster (cluster 3) showed IL-1, TNF, IFNα, and IFNγ perturbation-response signatures using Library of Integrated Network-Based Cellular Signatures (LINCS) 1000 ligand perturbation analysis. In addition, enrichment analysis revealed that cluster 3, as well as cluster 2 (i.e., AT1 cells) significantly enriched genes of BMI1 knockout mice that fail to self-renew their lung cells after damage.ConclusionThe current study shows that methotrexate exacerbates lung inflammation via attenuation of the regenerative potential of AT2 cells.References[1]Sakaguchi N, et al. Nature 2003;426:454.[2]Koenitzer JR, et al. Am J Respir Cell Mol Biol 2020;63:739.[3]Dovey JS, et al. Proc Natl Acad Sci USA 2008;105:11857.AcknowledgementsThis work was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant no.HI14C1277).Disclosure of InterestsNone declared.
Collapse
|
14
|
Yeo J, Yoon SH, Kim JY, Koo JM, Lee JS, Lee EY, Pourzand L, Goldin J, Kim G, Ha YJ. POS0068 CHANGES IN QUANTITATIVE INTERSTITIAL LUNG DISEASE SCORES ON HIGH-RESOLUTION CT IN IDIOPATHIC INFLAMMATORY MYOSITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundThe idiopathic inflammatory myopathies (IIM) are autoimmune connective tissue diseases affecting skeletal muscle, skin and other organ systems. IIM-related interstitial lung disease (IIM-ILD) is the most common extra-muscular manifestation, being the leading cause of morbidity and mortality. Several studies have suggested that ILD pattern based on chest high-resolution computed tomography (HRCT) can be related to disease course and treatment response, but the results vary considerably. Moreover, the clinical impact of the quantitative ILD (QILD) score, a validated computer-aided scoring system in assessing ILD severity from HRCT, and its longitudinal changes have not yet been evaluated in IIM-ILD.ObjectivesThis study aims to investigate ILD patterns and QILD scores in patients with IIM-ILD, to identify their clinical impact, and to delineate longitudinal changes of QILD measurement.MethodsA total of 80 patients with IIM (polymyositis 22, and dermatomyositis 58) who underwent at least 2 times of serial HRCT scans were included. Visual ILD patterns were assessed by multiple thoracic radiologists. Quantitative analysis of HRCT was presented as total extent of QILD scores (%) in whole lung and most severe zone. Individual time-estimated ΔQILD score between first 2 visits was derived using a linear approximation of yearly change, where the duration of median (IQR) was 1.0 (0.4-1.6) years in the first 2 HRCT scans.ResultsThe median (IQR) age of the patients was 52.0 (43.5-58.5) years and 60 (75.0%) were women. Baseline median score of whole lung-QILD and most severe zone-QILD were 28.1% (19.1-43.8) and 68.0% (45.5-81.8), respectively, and QILD score showed significant correlations with pulmonary function tests (r=-0.349, p=0.002 for % predicted forced vital capacity; and r=-0.381, p=0.001 for % predicted diffusing capacity for carbon monoxide). The individual time-estimated yearly ΔQILD score between first 2 visits presented that approximately half of the patients showed improvement or stability in QILD scores; however, when patients were sorted by visual assessment in ILD subtype on HRCT, approximately two-thirds of the patients with usual interstitial pneumonia (UIP) pattern were aggravated in QILD scores and less than half of subjects with nonspecific interstitial pneumonia and organizing pneumonia were aggravated (Figure 1, 80% for UIP vs. 44.4% for non-UIP, p=0.013). There was no immunosuppressive drugs related to meaningful improvement in QILD scores during first 2 visits. Notably, we observed significant aggravation of QILD scores in tacrolimus users (n=7, median time-estimated whole lung-yarly ΔQILD 20.3 (2.7-38.4)) compared with tacrolimus non-users (n=73, median time estimated whole lung-yearly ΔQILD -1.2 (-8.3-6.5)). Among 80 patients, 6 (7.5%) were died due to various lung complications. Higher baseline QILD scores were noted in deaths (median whole lung-QILD 45.4 (32.9-56.5)) than in survivors (median whole lung-QILD 26.9 (19.0-42.4)), albeit not significant (p=0.084). Poor survival rate was observed in patients with high grade of ground glass opacity by visual assessment in right upper lobe (log-rank test, p=0.042). Among subgroup of patients with 3 serial HRCT scans (n=41), dynamic changes of four distinct patterns (improving, worsening, convex, and concave) were observed.Figure 1.Cleveland dot plot of individual time-estimated yearly ΔQILD during fist 2 visits.ConclusionThe changes in QILD score in IIM-ILD are dynamic and present different by visual assessment. QILD score has the potential for evaluation of the severity changes, prognosis and medication response in patients with IIM-ILD.References[1]Tashkin DP, et al. Ann Rheum Dis 2016;75(2):374-81.7 truncated values in the graph A. NSIP: nonspecific interstitial pneumonia; OP: organizing pneumonia; UIP: usual interstitial pneumonia.Disclosure of InterestsNone declared
Collapse
|
15
|
Aaltonen T, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Appel JA, Arisawa T, Artikov A, Asaadi J, Ashmanskas W, Auerbach B, Aurisano A, Azfar F, Badgett W, Bae T, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barria P, Bartos P, Bauce M, Bedeschi F, Behari S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Bland KR, Blumenfeld B, Bocci A, Bodek A, Bortoletto D, Boudreau J, Boveia A, Brigliadori L, Bromberg C, Brucken E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Butti P, Buzatu A, Calamba A, Camarda S, Campanelli M, Carls B, Carlsmith D, Carosi R, Carrillo S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavaliere V, Cerri A, Cerrito L, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Cho K, Chokheli D, Clark A, Clarke C, Convery ME, Conway J, Corbo M, Cordelli M, Cox CA, Cox DJ, Cremonesi M, Cruz D, Cuevas J, Culbertson R, d'Ascenzo N, Datta M, de Barbaro P, Demortier L, Deninno M, D'Errico M, Devoto F, Di Canto A, Di Ruzza B, Dittmann JR, Donati S, D'Onofrio M, Dorigo M, Driutti A, Ebina K, Edgar R, Elagin A, Erbacher R, Errede S, Esham B, Farrington S, Fernández Ramos JP, Field R, Flanagan G, Forrest R, Franklin M, Freeman JC, Frisch H, Funakoshi Y, Galloni C, Garfinkel AF, Garosi P, Gerberich H, Gerchtein E, Giagu S, Giakoumopoulou V, Gibson K, Ginsburg CM, Giokaris N, Giromini P, Glagolev V, Glenzinski D, Gold M, Goldin D, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González López O, Gorelov I, Goshaw AT, Goulianos K, Gramellini E, Grosso-Pilcher C, Guimaraes da Costa J, Hahn SR, Han JY, Happacher F, Hara K, Hare M, Harr RF, Harrington-Taber T, Hatakeyama K, Hays C, Heinrich J, Herndon M, Hocker A, Hong Z, Hopkins W, Hou S, Hughes RE, Husemann U, Hussein M, Huston J, Introzzi G, Iori M, Ivanov A, James E, Jang D, Jayatilaka B, Jeon EJ, Jindariani S, Jones M, Joo KK, Jun SY, Junk TR, Kambeitz M, Kamon T, Karchin PE, Kasmi A, Kato Y, Ketchum W, Keung J, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SH, Kim SB, Kim YJ, Kim YK, Kimura N, Kirby M, Kondo K, Kong DJ, Konigsberg J, Kotwal AV, Kreps M, Kroll J, Kruse M, Kuhr T, Kurata M, Laasanen AT, Lammel S, Lancaster M, Lannon K, Latino G, Lee HS, Lee JS, Leo S, Leone S, Lewis JD, Limosani A, Lipeles E, Lister A, Liu Q, Liu T, Lockwitz S, Loginov A, Lucchesi D, Lucà A, Lueck J, Lujan P, Lukens P, Lungu G, Lys J, Lysak R, Madrak R, Maestro P, Malik S, Manca G, Manousakis-Katsikakis A, Marchese L, Margaroli F, Marino P, Matera K, Mattson ME, Mazzacane A, Mazzanti P, McNulty R, Mehta A, Mehtala P, Menzione A, Mesropian C, Miao T, Michielin E, Mietlicki D, Mitra A, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello MJ, Mukherjee A, Muller T, Murat P, Mussini M, Nachtman J, Nagai Y, Naganoma J, Nakano I, Napier A, Nett J, Nigmanov T, Nodulman L, Noh SY, Norniella O, Oakes L, Oh SH, Oh YD, Okusawa T, Orava R, Ortolan L, Pagliarone C, Palencia E, Palni P, Papadimitriou V, Parker W, Pauletta G, Paulini M, Paus C, Phillips TJ, Piacentino G, Pianori E, Pilot J, Pitts K, Plager C, Pondrom L, Poprocki S, Potamianos K, Pranko A, Prokoshin F, Ptohos F, Punzi G, Redondo Fernández I, Renton P, Rescigno M, Rimondi F, Ristori L, Robson A, Rodriguez T, Rolli S, Ronzani M, Roser R, Rosner JL, Ruffini F, Ruiz A, Russ J, Rusu V, Sakumoto WK, Sakurai Y, Santi L, Sato K, Saveliev V, Savoy-Navarro A, Schlabach P, Schmidt EE, Schwarz T, Scodellaro L, Scuri F, Seidel S, Seiya Y, Semenov A, Sforza F, Shalhout SZ, Shears T, Shepard PF, Shimojima M, Shochet M, Shreyber-Tecker I, Simonenko A, Sliwa K, Smith JR, Snider FD, Song H, Sorin V, St Denis R, Stancari M, Stentz D, Strologas J, Sudo Y, Sukhanov A, Suslov I, Takemasa K, Takeuchi Y, Tang J, Tecchio M, Teng PK, Thom J, Thomson E, Thukral V, Toback D, Tokar S, Tollefson K, Tomura T, Torre S, Torretta D, Totaro P, Trovato M, Ukegawa F, Uozumi S, Vázquez F, Velev G, Vellidis K, Vernieri C, Vidal M, Vilar R, Vizán J, Vogel M, Volpi G, Wagner P, Wallny R, Wang SM, Waters D, Wester WC, Whiteson D, Wicklund AB, Wilbur S, Williams HH, Wilson JS, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfmeister H, Wright T, Wu X, Wu Z, Yamamoto K, Yamato D, Yang T, Yang UK, Yang YC, Yao WM, Yeh GP, Yi K, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Zanetti AM, Zeng Y, Zhou C, Zucchelli S. High-precision measurement of the W boson mass with the CDF II detector. Science 2022; 376:170-176. [PMID: 35389814 DOI: 10.1126/science.abk1781] [Citation(s) in RCA: 77] [Impact Index Per Article: 38.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The mass of the W boson, a mediator of the weak force between elementary particles, is tightly constrained by the symmetries of the standard model of particle physics. The Higgs boson was the last missing component of the model. After observation of the Higgs boson, a measurement of the W boson mass provides a stringent test of the model. We measure the W boson mass, MW, using data corresponding to 8.8 inverse femtobarns of integrated luminosity collected in proton-antiproton collisions at a 1.96 tera-electron volt center-of-mass energy with the CDF II detector at the Fermilab Tevatron collider. A sample of approximately 4 million W boson candidates is used to obtain [Formula: see text], the precision of which exceeds that of all previous measurements combined (stat, statistical uncertainty; syst, systematic uncertainty; MeV, mega-electron volts; c, speed of light in a vacuum). This measurement is in significant tension with the standard model expectation.
Collapse
Affiliation(s)
| | - T Aaltonen
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - S Amerio
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - D Amidei
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Anastassov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Annovi
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - J Antos
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - G Apollinari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J A Appel
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - A Artikov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - J Asaadi
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - W Ashmanskas
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - B Auerbach
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - A Aurisano
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - F Azfar
- University of Oxford, Oxford OX1 3RH, UK
| | - W Badgett
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - T Bae
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - A Barbaro-Galtieri
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - V E Barnes
- Purdue University, West Lafayette, IN 47907, USA
| | - B A Barnett
- The Johns Hopkins University, Baltimore, MD 21218, USA
| | - P Barria
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - P Bartos
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - M Bauce
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - F Bedeschi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Behari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Bellettini
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - J Bellinger
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | | | - A Beretvas
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Bhatti
- The Rockefeller University, New York, NY 10065, USA
| | - K R Bland
- Baylor University, Waco, TX 76798, USA
| | - B Blumenfeld
- The Johns Hopkins University, Baltimore, MD 21218, USA
| | - A Bocci
- Duke University, Durham, NC 27708, USA
| | - A Bodek
- University of Rochester, Rochester, NY 14627, USA
| | - D Bortoletto
- Purdue University, West Lafayette, IN 47907, USA
| | - J Boudreau
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - A Boveia
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - L Brigliadori
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - C Bromberg
- Michigan State University, East Lansing, MI 48824, USA
| | - E Brucken
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - J Budagov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - H S Budd
- University of Rochester, Rochester, NY 14627, USA
| | - K Burkett
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Busetto
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - P Bussey
- Glasgow University, Glasgow G12 8QQ, UK
| | - P Butti
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - A Buzatu
- Glasgow University, Glasgow G12 8QQ, UK
| | - A Calamba
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - S Camarda
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | | | - B Carls
- University of Illinois, Urbana, IL 61801, USA
| | - D Carlsmith
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - R Carosi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Carrillo
- University of Florida, Gainesville, FL 32611, USA
| | - B Casal
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - M Casarsa
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - A Castro
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - P Catastini
- Harvard University, Cambridge, MA 02138, USA
| | - D Cauz
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - V Cavaliere
- University of Illinois, Urbana, IL 61801, USA
| | - A Cerri
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - L Cerrito
- University College London, London WC1E 6BT, UK
| | - Y C Chen
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - M Chertok
- University of California, Davis, Davis, CA 95616, USA
| | - G Chiarelli
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - G Chlachidze
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Cho
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - D Chokheli
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - A Clark
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - C Clarke
- Wayne State University, Detroit, MI 48201, USA
| | - M E Convery
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Conway
- University of California, Davis, Davis, CA 95616, USA
| | - M Corbo
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Cordelli
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - C A Cox
- University of California, Davis, Davis, CA 95616, USA
| | - D J Cox
- University of California, Davis, Davis, CA 95616, USA
| | - M Cremonesi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - D Cruz
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - J Cuevas
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - R Culbertson
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N d'Ascenzo
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Datta
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P de Barbaro
- University of Rochester, Rochester, NY 14627, USA
| | - L Demortier
- The Rockefeller University, New York, NY 10065, USA
| | - M Deninno
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - M D'Errico
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - F Devoto
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - A Di Canto
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - B Di Ruzza
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - S Donati
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - M D'Onofrio
- University of Liverpool, Liverpool L69 7ZE, UK
| | - M Dorigo
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,University of Trieste, I-34127 Trieste, Italy
| | - A Driutti
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - K Ebina
- Waseda University, Tokyo 169, Japan
| | - R Edgar
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Elagin
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - R Erbacher
- University of California, Davis, Davis, CA 95616, USA
| | - S Errede
- University of Illinois, Urbana, IL 61801, USA
| | - B Esham
- University of Illinois, Urbana, IL 61801, USA
| | | | - J P Fernández Ramos
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - R Field
- University of Florida, Gainesville, FL 32611, USA
| | - G Flanagan
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - R Forrest
- University of California, Davis, Davis, CA 95616, USA
| | - M Franklin
- Harvard University, Cambridge, MA 02138, USA
| | - J C Freeman
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - H Frisch
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | | | - C Galloni
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | | | - P Garosi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - H Gerberich
- University of Illinois, Urbana, IL 61801, USA
| | - E Gerchtein
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Giagu
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - V Giakoumopoulou
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - K Gibson
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - C M Ginsburg
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N Giokaris
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - P Giromini
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - V Glagolev
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - D Glenzinski
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Gold
- University of New Mexico, Albuquerque, NM 87131, USA
| | - D Goldin
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - A Golossanov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Gomez
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | | | - M Goncharov
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - O González López
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - I Gorelov
- University of New Mexico, Albuquerque, NM 87131, USA
| | | | - K Goulianos
- The Rockefeller University, New York, NY 10065, USA
| | - E Gramellini
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - C Grosso-Pilcher
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | | | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Y Han
- University of Rochester, Rochester, NY 14627, USA
| | - F Happacher
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - K Hara
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - M Hare
- Tufts University, Medford, MA 02155, USA
| | - R F Harr
- Wayne State University, Detroit, MI 48201, USA
| | | | | | - C Hays
- University of Oxford, Oxford OX1 3RH, UK
| | - J Heinrich
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - M Herndon
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - A Hocker
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Z Hong
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - W Hopkins
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Hou
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - R E Hughes
- The Ohio State University, Columbus, OH 43210, USA
| | - U Husemann
- Yale University, New Haven, CT 06520, USA
| | - M Hussein
- Michigan State University, East Lansing, MI 48824, USA
| | - J Huston
- Michigan State University, East Lansing, MI 48824, USA
| | - G Introzzi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Istituto Nazionale di Fisica Nucleare Pavia, I-27100 Pavia, Italy.,University of Pavia, I-27100 Pavia, Italy
| | - M Iori
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy.,Sapienza Università di Roma, I-00185 Roma, Italy
| | - A Ivanov
- University of California, Davis, Davis, CA 95616, USA
| | - E James
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Jang
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - B Jayatilaka
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E J Jeon
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Jindariani
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Jones
- Purdue University, West Lafayette, IN 47907, USA
| | - K K Joo
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Y Jun
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - T R Junk
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Kambeitz
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - T Kamon
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA.,Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - P E Karchin
- Wayne State University, Detroit, MI 48201, USA
| | - A Kasmi
- Baylor University, Waco, TX 76798, USA
| | - Y Kato
- Osaka City University, Osaka 558-8585, Japan
| | - W Ketchum
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - J Keung
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - B Kilminster
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D H Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - H S Kim
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J E Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - M J Kim
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - S H Kim
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S B Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y J Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y K Kim
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - N Kimura
- Waseda University, Tokyo 169, Japan
| | - M Kirby
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Kondo
- Waseda University, Tokyo 169, Japan
| | - D J Kong
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - J Konigsberg
- University of Florida, Gainesville, FL 32611, USA
| | | | - M Kreps
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - J Kroll
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - M Kruse
- Duke University, Durham, NC 27708, USA
| | - T Kuhr
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - M Kurata
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - A T Laasanen
- Purdue University, West Lafayette, IN 47907, USA
| | - S Lammel
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Lancaster
- University College London, London WC1E 6BT, UK
| | - K Lannon
- The Ohio State University, Columbus, OH 43210, USA
| | - G Latino
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - H S Lee
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - J S Lee
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Leo
- University of Illinois, Urbana, IL 61801, USA
| | - S Leone
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - J D Lewis
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - E Lipeles
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - A Lister
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - Q Liu
- Purdue University, West Lafayette, IN 47907, USA
| | - T Liu
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Lockwitz
- Yale University, New Haven, CT 06520, USA
| | - A Loginov
- Yale University, New Haven, CT 06520, USA
| | - D Lucchesi
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - A Lucà
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA.,Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - J Lueck
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - P Lujan
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - P Lukens
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Lungu
- The Rockefeller University, New York, NY 10065, USA
| | - J Lys
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - R Lysak
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - R Madrak
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Maestro
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - S Malik
- The Rockefeller University, New York, NY 10065, USA
| | - G Manca
- University of Liverpool, Liverpool L69 7ZE, UK
| | | | - L Marchese
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - F Margaroli
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - P Marino
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - K Matera
- University of Illinois, Urbana, IL 61801, USA
| | - M E Mattson
- Wayne State University, Detroit, MI 48201, USA
| | - A Mazzacane
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Mazzanti
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - R McNulty
- University of Liverpool, Liverpool L69 7ZE, UK
| | - A Mehta
- University of Liverpool, Liverpool L69 7ZE, UK
| | - P Mehtala
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - A Menzione
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - C Mesropian
- The Rockefeller University, New York, NY 10065, USA
| | - T Miao
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Michielin
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - D Mietlicki
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Mitra
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - H Miyake
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Moed
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N Moggi
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - C S Moon
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - R Moore
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M J Morello
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - A Mukherjee
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Th Muller
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - P Murat
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Mussini
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - J Nachtman
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Y Nagai
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | | | - I Nakano
- Okayama University, Okayama 700-8530, Japan
| | - A Napier
- Tufts University, Medford, MA 02155, USA
| | - J Nett
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - T Nigmanov
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - L Nodulman
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - S Y Noh
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - O Norniella
- University of Illinois, Urbana, IL 61801, USA
| | - L Oakes
- University of Oxford, Oxford OX1 3RH, UK
| | - S H Oh
- Duke University, Durham, NC 27708, USA
| | - Y D Oh
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - T Okusawa
- Osaka City University, Osaka 558-8585, Japan
| | - R Orava
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - L Ortolan
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | - C Pagliarone
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - E Palencia
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - P Palni
- University of New Mexico, Albuquerque, NM 87131, USA
| | - V Papadimitriou
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - W Parker
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - G Pauletta
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - M Paulini
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - C Paus
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | - G Piacentino
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Pianori
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - J Pilot
- University of California, Davis, Davis, CA 95616, USA
| | - K Pitts
- University of Illinois, Urbana, IL 61801, USA
| | - C Plager
- University of California, Los Angeles, Los Angeles, CA 90024, USA
| | - L Pondrom
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - S Poprocki
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Potamianos
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - A Pranko
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - F Prokoshin
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - F Ptohos
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - G Punzi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - I Redondo Fernández
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - P Renton
- University of Oxford, Oxford OX1 3RH, UK
| | - M Rescigno
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - F Rimondi
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - L Ristori
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA.,Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - A Robson
- Glasgow University, Glasgow G12 8QQ, UK
| | - T Rodriguez
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - S Rolli
- Tufts University, Medford, MA 02155, USA
| | - M Ronzani
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - R Roser
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J L Rosner
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - F Ruffini
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - A Ruiz
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - J Russ
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - V Rusu
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - W K Sakumoto
- University of Rochester, Rochester, NY 14627, USA
| | | | - L Santi
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - K Sato
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - V Saveliev
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Savoy-Navarro
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Schlabach
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E E Schmidt
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - T Schwarz
- University of Michigan, Ann Arbor, MI 48109, USA
| | - L Scodellaro
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - F Scuri
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Seidel
- University of New Mexico, Albuquerque, NM 87131, USA
| | - Y Seiya
- Osaka City University, Osaka 558-8585, Japan
| | - A Semenov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - F Sforza
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - S Z Shalhout
- University of California, Davis, Davis, CA 95616, USA
| | - T Shears
- University of Liverpool, Liverpool L69 7ZE, UK
| | - P F Shepard
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - M Shimojima
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - M Shochet
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - I Shreyber-Tecker
- Institution for Theoretical and Experimental Physics, ITEP, Moscow 117259, Russia
| | - A Simonenko
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - K Sliwa
- Tufts University, Medford, MA 02155, USA
| | - J R Smith
- University of California, Davis, Davis, CA 95616, USA
| | - F D Snider
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - H Song
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - V Sorin
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | | | - M Stancari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Stentz
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Strologas
- University of New Mexico, Albuquerque, NM 87131, USA
| | - Y Sudo
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - A Sukhanov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - I Suslov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - K Takemasa
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - Y Takeuchi
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - J Tang
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - M Tecchio
- University of Michigan, Ann Arbor, MI 48109, USA
| | - P K Teng
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - J Thom
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Thomson
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - V Thukral
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - D Toback
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - S Tokar
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - K Tollefson
- Michigan State University, East Lansing, MI 48824, USA
| | - T Tomura
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Torre
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Totaro
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy
| | - M Trovato
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - F Ukegawa
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Uozumi
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - F Vázquez
- University of Florida, Gainesville, FL 32611, USA
| | - G Velev
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Vellidis
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - C Vernieri
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - M Vidal
- Purdue University, West Lafayette, IN 47907, USA
| | - R Vilar
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - J Vizán
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - M Vogel
- University of New Mexico, Albuquerque, NM 87131, USA
| | - G Volpi
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - P Wagner
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - R Wallny
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S M Wang
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - D Waters
- University College London, London WC1E 6BT, UK
| | - W C Wester
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Whiteson
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - A B Wicklund
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - S Wilbur
- University of California, Davis, Davis, CA 95616, USA
| | - H H Williams
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - J S Wilson
- University of Michigan, Ann Arbor, MI 48109, USA
| | - P Wilson
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - B L Winer
- The Ohio State University, Columbus, OH 43210, USA
| | - P Wittich
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Wolbers
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - T Wright
- University of Michigan, Ann Arbor, MI 48109, USA
| | - X Wu
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - Z Wu
- Baylor University, Waco, TX 76798, USA
| | - K Yamamoto
- Osaka City University, Osaka 558-8585, Japan
| | - D Yamato
- Osaka City University, Osaka 558-8585, Japan
| | - T Yang
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - U K Yang
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y C Yang
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - W-M Yao
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - G P Yeh
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Yi
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Yoh
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Yorita
- Waseda University, Tokyo 169, Japan
| | - T Yoshida
- Osaka City University, Osaka 558-8585, Japan
| | - G B Yu
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - I Yu
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - A M Zanetti
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - Y Zeng
- Duke University, Durham, NC 27708, USA
| | - C Zhou
- Duke University, Durham, NC 27708, USA
| | - S Zucchelli
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| |
Collapse
|
16
|
Jo S, Lee JS, Nam B, Lee YL, Kim H, Lee EY, Park YS, Kim TH. SOX9 + enthesis cells are associated with spinal ankylosis in ankylosing spondylitis. Osteoarthritis Cartilage 2022; 30:280-290. [PMID: 34826571 DOI: 10.1016/j.joca.2021.11.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 11/09/2021] [Accepted: 11/17/2021] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Although cartilage degeneration and invasion of the subchondral bone plate in entheseal lesion has been considered to consequently lead bony ankylosis in ankylosing spondylitis (AS), no evident mechanisms are known. DESIGN To identify histopathological and physiological changes in enthesitis-related ankylosis in AS, we performed molecular characterization of transcription factors and surface markers, and transcriptome analysis with human tissues. Entheseal tissue containing subchondral bone was obtained from the facet joints of 9 patients with AS and 10 disease controls, and assessed by using differential staining techniques. Enthesis cells were isolated, characterized, stimulated with TNF and/or IL-17A, and analysed by cell-based experimental tools. RESULTS We found diffusely distributed granular tissue and cartilage in the subchondral bone in AS. Co-expression of SOX9, a specific transcription factor in cartilage, and matrix metalloproteinase 13 (MMP13) was found in the granular tissues within the subchondral bone from AS patients. Intriguingly, SOX9 expression was significantly higher in AS enthesis cells than controls and correlated with TNFR1 and IL-17RA expressions, which is important for high reactivity to TNF and IL-17A cytokines. Co-stimulation by TNF and IL-17A resulted in accelerated mineralization/calcification features, and increased OCN expression in AS enthesis cells. Furthermore, SOX9 overexpression in enthesis leads to promoting mineralization feature by TNF and IL-17A stimuli. Finally, OCN expression is elevated in the destructive enthesis of advanced AS. CONCLUSION These findings provide insight into the links between inflammation and the mineralization of entheseal tissue as the initiation of spinal ankylosis, emphasizing the importance of SOX9+ enthesis cells.
Collapse
Affiliation(s)
- S Jo
- Hanyang University Institute for Rheumatology Research, Hanyang University Hospital for Rheumatic Diseases, Seoul 04763, Republic of Korea
| | - J S Lee
- Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea; GENOME INSIGHT Inc., Daejeon 34141, Republic of Korea
| | - B Nam
- Hanyang University Institute for Rheumatology Research, Hanyang University Hospital for Rheumatic Diseases, Seoul 04763, Republic of Korea
| | - Y L Lee
- Hanyang University Institute for Rheumatology Research, Hanyang University Hospital for Rheumatic Diseases, Seoul 04763, Republic of Korea
| | - H Kim
- Department of Pathology, Hanyang University Seoul Hospital, Seoul 04763, Republic of Korea
| | - E Y Lee
- Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Y-S Park
- Department of Orthopedic Surgery, Guri Hospital, Hanyang University College of Medicine, Guri 11923, Republic of Korea
| | - T-H Kim
- Hanyang University Institute for Rheumatology Research, Hanyang University Hospital for Rheumatic Diseases, Seoul 04763, Republic of Korea; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 04763, Republic of Korea.
| |
Collapse
|
17
|
Orth M, Fritz T, Stutz J, Scheuer C, Ganse B, Bullinger Y, Lee JS, Murphy WL, Laschke MW, Menger MD, Pohlemann T. Local Application of Mineral-Coated Microparticles Loaded With VEGF and BMP-2 Induces the Healing of Murine Atrophic Non-Unions. Front Bioeng Biotechnol 2022; 9:809397. [PMID: 35087807 PMCID: PMC8787303 DOI: 10.3389/fbioe.2021.809397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Accepted: 12/23/2021] [Indexed: 11/17/2022] Open
Abstract
Deficient angiogenesis and disturbed osteogenesis are key factors for the development of nonunions. Mineral-coated microparticles (MCM) represent a sophisticated carrier system for the delivery of vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP)-2. In this study, we investigated whether a combination of VEGF- and BMP-2-loaded MCM (MCM + VB) with a ratio of 1:2 improves bone repair in non-unions. For this purpose, we applied MCM + VB or unloaded MCM in a murine non-union model and studied the process of bone healing by means of radiological, biomechanical, histomorphometric, immunohistochemical and Western blot techniques after 14 and 70 days. MCM-free non-unions served as controls. Bone defects treated with MCM + VB exhibited osseous bridging, an improved biomechanical stiffness, an increased bone volume within the callus including ongoing mineralization, increased vascularization, and a histologically larger total periosteal callus area consisting predominantly of osseous tissue when compared to defects of the other groups. Western blot analyses on day 14 revealed a higher expression of osteoprotegerin (OPG) and vice versa reduced expression of receptor activator of NF-κB ligand (RANKL) in bone defects treated with MCM + VB. On day 70, these defects exhibited an increased expression of erythropoietin (EPO), EPO-receptor and BMP-4. These findings indicate that the use of MCM for spatiotemporal controlled delivery of VEGF and BMP-2 shows great potential to improve bone healing in atrophic non-unions by promoting angiogenesis and osteogenesis as well as reducing early osteoclast activity.
Collapse
Affiliation(s)
- M Orth
- Department of Trauma, Hand and Reconstructive Surgery, Saarland University, Homburg, Germany.,Institute for Clinical and Experimental Surgery, Saarland University, Homburg, Germany
| | - T Fritz
- Department of Trauma, Hand and Reconstructive Surgery, Saarland University, Homburg, Germany
| | - J Stutz
- Department of Trauma, Hand and Reconstructive Surgery, Saarland University, Homburg, Germany.,Institute for Clinical and Experimental Surgery, Saarland University, Homburg, Germany
| | - C Scheuer
- Institute for Clinical and Experimental Surgery, Saarland University, Homburg, Germany
| | - B Ganse
- Department of Trauma, Hand and Reconstructive Surgery, Saarland University, Homburg, Germany.,Werner Siemens Endowed Chair of Innovative Implant Development (Fracture Healing), Saarland University, Homburg, Germany
| | - Y Bullinger
- Department of Trauma, Hand and Reconstructive Surgery, Saarland University, Homburg, Germany
| | - J S Lee
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, United States
| | - W L Murphy
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, United States
| | - M W Laschke
- Institute for Clinical and Experimental Surgery, Saarland University, Homburg, Germany
| | - M D Menger
- Institute for Clinical and Experimental Surgery, Saarland University, Homburg, Germany
| | - T Pohlemann
- Department of Trauma, Hand and Reconstructive Surgery, Saarland University, Homburg, Germany
| |
Collapse
|
18
|
Park SH, Goh TS, Park YG, Kim DS, Lee JS. Validation of a Korean version of the quality-of-life profile for spine deformities (QLPSD) in patients with adolescent idiopathic scoliosis. Eur Rev Med Pharmacol Sci 2022; 26:84-89. [PMID: 35049023 DOI: 10.26355/eurrev_202201_27751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
OBJECTIVE We aimed to evaluate the reliability and validity of the adapted Korean version of the Quality-of-Life Profile for Spine Deformities (QLPSD) questionnaire. PATIENTS AND METHODS English version of QLPSD was translated into Korean according to previously published guidelines. The Korean version of the QLPSD questionnaire and the Korean version of the SRS-22 was sent to 120 consecutive idiopathic scoliosis patients wearing braces recruited from the outpatient clinic. Reliability assessment and construct validity were evaluated. RESULTS The intraobserver reliability of all items in the questionnaire had a kappa statistic of agreement greater than 0.6. The QLPSD showed good test/re-test reliability (ICC = 0.815). The internal consistency of Cronbach's α was found to be very good (α = 0.918). The Korean version of QLPSD showed a significant correlation with the SRS-22 total score (p<0.001, r=-0.811) and single SRS-22 domains scores. CONCLUSIONS The adapted Korean version of the QLPSD was successfully translated and showed good measurement properties. As such, it is considered suitable for outcome assessments in Korean-speaking patients with idiopathic scoliosis.
Collapse
Affiliation(s)
- S H Park
- Department of Orthopaedic Surgery, Gupo Sungshim Hospital, Busan, Republic of Korea.
| | | | | | | | | |
Collapse
|
19
|
Kim CH, Jo M, Lee JS, Bianconi G, Kahng B. Link overlap influences opinion dynamics on multiplex networks of Ashkin-Teller spins. Phys Rev E 2021; 104:064304. [PMID: 35030955 DOI: 10.1103/physreve.104.064304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2021] [Accepted: 11/22/2021] [Indexed: 06/14/2023]
Abstract
Consider a multiplex network formed by two layers indicating social interactions: the first layer is a friendship network and the second layer is a network of business relations. In this duplex network each pair of individuals can be connected in different ways: they can be connected by a friendship but not connected by a business relation, they can be connected by a business relation without being friends, or they can be simultaneously friends and in a business relation. In the latter case we say that the links in different layers overlap. These three types of connections are called multilinks and the multidegree indicates the sum of multilinks of a given type that are incident to a given node. Previous opinion models on multilayer networks have mostly neglected the effect of link overlap. Here we show that link overlap can have important effects in the formation of a majority opinion. Indeed, the formation of a majority opinion can be significantly influenced by the statistical properties of multilinks, and in particular by the multidegree distribution. To quantitatively address this problem, we study a simple spin model, called the Ashkin-Teller model, including two-body and four-body interactions between nodes in different layers. Here we fully investigate the rich phase diagram of this model which includes a large variety of phase transitions. Indeed, the phase diagram or the model displays continuous, discontinuous, and hybrid phase transitions, and successive jumps of the order parameters within the Baxter phase.
Collapse
Affiliation(s)
- Cook Hyun Kim
- CCSS, CTP and Department of Physics and Astronomy, Seoul National University, Seoul 08826, Korea
| | - Minjae Jo
- CCSS, CTP and Department of Physics and Astronomy, Seoul National University, Seoul 08826, Korea
| | - J S Lee
- School of Physics, Korea Institute for Advanced Study, Seoul 02455, Korea
| | - G Bianconi
- School of Mathematical Sciences, Queen Mary University of London, E1 4GF, London, United Kingdom
- Alan Turing Institute, The British Library, NW1 2DB, London, United Kingdom
| | - B Kahng
- Center for Complex Systems, KI of Grid Modernization, Korea Institute of Energy Technology, Naju, Jeonnam 58217, Korea
| |
Collapse
|
20
|
Fleckenstein J, Milliken JT, Lee JS, Ballentine SJ. Cystic angiomatosis of the bone, liver, and spleen. Am J Clin Pathol 2021. [DOI: 10.1093/ajcp/aqab191.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Introduction/Objective
Cystic angiomatosis is a very rare entity characterized by multifocal cystic angiomatous lesions of the skeletal system, occasionally involving visceral organ systems. Clinical presentation and progression are extremely variable. Cases with liver involvement are even rarer, and have been described as invariably fatal. The pathogenesis of this disorder is poorly understood, and no treatments are currently available.
Methods/Case Report
A 24 year old man with history of polysubstance abuse and untreated hepatitis C presented with acute abdominal pain. Imaging revealed hepatosplenomegaly and multiple liver, spleen, and skeletal lesions. Differential diagnoses included metastatic disease, lymphoma, and infection. Apart from known untreated chronic hepatitis C, all infectious, autoimmune and hypercoagulability work-ups were negative. Biopsies of the liver and iliac bone lesions showed areas of benign-appearing vascular proliferation in a background of fibrosis. The vascular endothelial cells were positive for CD34 and CD31 but negative for D2-40. On follow-up approximately eight months later, the patient was asymptomatic.
Results (if a Case Study enter NA)
NA
Conclusion
Liver involvement by cystic angiomatosis is exceedingly rare and has been associated with increased mortality. This case provides an example of a patient with incidentally discovered cystic angiomatosis involving liver, spleen, and bone who remains asymptomatic at follow-up. Additional cases are required to understand the pathophysiology and disease course in this group of patients, and to investigate possible therapeutic targets.
Collapse
Affiliation(s)
- J Fleckenstein
- Department of Medicine, Washington University, St. Louis, Missouri, UNITED STATES
| | - John T Milliken
- Department of Medicine, Washington University, St. Louis, Missouri, UNITED STATES
| | - J S Lee
- Department of Pathology & Immunology, Washington University, St. Louis, Missouri, UNITED STATES
| | - S J Ballentine
- Department of Pathology & Immunology, Washington University, St. Louis, Missouri, UNITED STATES
| |
Collapse
|
21
|
Valderrábano RJ, Buzkova P, Chang PY, Zakai NA, Fink HA, Robbins JA, Wu JY, Lee JS. Associations of hemoglobin and change in hemoglobin with risk of incident hip fracture in older men and women: the cardiovascular health study. Osteoporos Int 2021; 32:1669-1677. [PMID: 33576845 PMCID: PMC8764634 DOI: 10.1007/s00198-021-05873-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 02/01/2021] [Indexed: 12/18/2022]
Abstract
UNLABELLED In a multi-site longitudinal cohort study, decreasing hemoglobin was associated with increased hip fracture risk in men. Anemia was associated with hip fracture in men and in African American women. Decreasing hemoglobin may be a marker of progressing bone fragility, making its serial measurement useful for fracture risk stratification. INTRODUCTION Hematopoiesis and bone health are interdependent. Anemia has been associated with risk of fracture in humans. To further elucidate this relationship, we hypothesized that decreasing hemoglobin could indicate defective hematopoiesis and would also predict fracture risk. METHODS We performed a prospective analysis from study baseline (1992) of the Cardiovascular Health Study, a multi-site longitudinal cohort study. A total of 4670 men and women, ages >65 years, who were able to consent and not institutionalized or wheelchair bound, had hemoglobin (Hb) measured in 1992. For 4006 subjects, Hb change from 1989 to 1992 was annualized and divided into sex-specific quartiles. Incident hip fractures were verified against Medicare claims data during a median follow-up of 11.8 years. RESULTS Nested Cox proportional-hazard models estimated association of hip fracture with anemia (men Hb <13 g/dL, women Hb <12 g/dL) and separately, greatest Hb decrease (versus others). Anemia was associated with increased hip fracture risk in all men (HR 1.59; 95% CI 1.01-2.50) and African American women (HR 3.21; 95% CI 1.07-9.63). In men, an annualized Hb loss of >0.36 g/dL/year was associated with a higher risk of hip fracture (HR 1.67; 95% CI 1.10-2.54), which was lessened by anemia at the start of fracture follow-up (HR 1.53; 95% CI 0.99-2.39). CONCLUSIONS Decreasing Hb may be an early marker for subsequent hip fracture risk in men, which may be less informative once an anemia threshold is crossed. Only African American women with anemia had increased hip fracture risk, suggesting a race difference in this relationship.
Collapse
Affiliation(s)
- R J Valderrábano
- University of Miami Miller School of Medicine, P.O. Box 016960 (D-56), Miami, FL, 33101, USA.
- Division of Endocrinology, Stanford University School of Medicine, 300 Pasteur Dr., S-025, Stanford, CA, 94305, USA.
| | - P Buzkova
- Department of Biostatistics, University of Washington, Seattle, WA, USA
| | - P-Y Chang
- Division of Endocrinology, Stanford University School of Medicine, 300 Pasteur Dr., S-025, Stanford, CA, 94305, USA
- School of Medicine, University of California, Davis, CA, USA
| | - N A Zakai
- Department of Medicine and Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA
| | - H A Fink
- GRECC, Veteran Affairs Health Care System, Minneapolis, MN, USA
| | - J A Robbins
- School of Medicine, University of California, Davis, CA, USA
| | - J Y Wu
- Division of Endocrinology, Stanford University School of Medicine, 300 Pasteur Dr., S-025, Stanford, CA, 94305, USA.
| | - J S Lee
- Division of Endocrinology, Stanford University School of Medicine, 300 Pasteur Dr., S-025, Stanford, CA, 94305, USA
- Palo Alto Veteran Affairs Health Care System, Palo Alto, CA, USA
| | | |
Collapse
|
22
|
Jang SH, Sohn SI, Park H, Lee SJ, Kim YW, Hong JM, Kim CH, Choi JW, Kang DH, Kim YS, Hwang YH, Lee JS, Hong JH. The Safety of Intra-arterial Tirofiban during Endovascular Therapy after Intravenous Thrombolysis. AJNR Am J Neuroradiol 2021; 42:1633-1637. [PMID: 34301637 DOI: 10.3174/ajnr.a7203] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Accepted: 04/07/2021] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE The safety and efficacy of tirofiban during endovascular therapy in patients undergoing intravenous thrombolysis with recombinant IV tPA remain unclear. This study aimed to investigate the safety and efficacy of intra-arterial tirofiban use during endovascular therapy in patients treated with IV tPA. MATERIALS AND METHODS Using a multicenter registry, we enrolled patients with acute ischemic stroke who underwent endovascular therapy. Safety outcomes included postprocedural parenchymal hematoma type 2 and/or thick subarachnoid hemorrhage, intraventricular hemorrhage, and 3-month mortality. Efficacy outcomes included the successful reperfusion rate, postprocedural reocclusion, and good outcomes at 3 months (mRS scores of 0-2). The tirofiban effect on the outcomes was evaluated using a multivariable analysis while adjusting for potential confounders. RESULTS Among enrolled patients, we identified 314 patients with stroke (279 and 35 patients in the no tirofiban and tirofiban groups, respectively) due to an intracranial artery occlusion who underwent endovascular therapy with intravenous thrombolysis. A multivariable analysis revealed no association of intra-arterial tirofiban with postprocedural parenchymal hematoma type and/or thick subarachnoid hemorrhage (adjusted OR, 1.07; 95% CI, 0.20-4.10; P = .918), intraventricular hemorrhage (adjusted OR, 0.43; 95% CI, 0.02-2.85; P = .467), and 3-month mortality (adjusted OR, 0.38; 95% CI, 0.04-1.87; P = .299). Intra-arterial tirofiban was not associated with good outcome (adjusted OR, 2.22; 95% CI, 0.89 -6.12; P = .099). CONCLUSIONS Using intra-arterial tirofiban during endovascular therapy after IV tPA could be safe.
Collapse
Affiliation(s)
- S H Jang
- From the Departments of Neurology (S.H.J., S.-I.S., H.P., J.-H.H.)
| | - S-I Sohn
- From the Departments of Neurology (S.H.J., S.-I.S., H.P., J.-H.H.)
| | - H Park
- From the Departments of Neurology (S.H.J., S.-I.S., H.P., J.-H.H.)
| | - S-J Lee
- Department of Neurology (S.-J.L., J.M.H., J.S.L.)
| | - Y-W Kim
- Department of Neurology (Y.-W.K., Y.-H.H.)
| | - J M Hong
- Department of Neurology (S.-J.L., J.M.H., J.S.L.)
| | - C-H Kim
- Neurosurgery (C.-H.K.), School of Medicine Keimyung University, Daegu, South Korea
| | - J W Choi
- Radiology (J.W.C.), School of Medicine, Ajou University, Suwon, South Korea
| | | | - Y-S Kim
- Radiology (Y.-S.K.), School of Medicine, Kyungpook National University, Daegu, South Korea
| | - Y-H Hwang
- Department of Neurology (Y.-W.K., Y.-H.H.)
| | - J S Lee
- Department of Neurology (S.-J.L., J.M.H., J.S.L.)
| | - J-H Hong
- From the Departments of Neurology (S.H.J., S.-I.S., H.P., J.-H.H.)
| |
Collapse
|
23
|
Lee SJ, Lee JS, Cha UC, Nam EJ. POS0936 TREATMENT OF ANKYLOSING SPONDYLITIS WITH TUMOR NECROSIS FACTOR-ALPHA INHIBITORS LOWERS THE RISK OF RENAL FUNCTION DECLINE. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Ankylosing spondylitis (AS) is associated with reduced renal function, possibly due to chronic inflammation or the use of nephrotoxic drugs. However, the long term effect of tumor necrosis factor (TNF) inhibitors on renal function in patients with AS has not been well established.Objectives:We therefore investigated the association of TNF inhibitors treatment and change in estimated glomerular filtration rate (GFR) using the Korean College of Rheumatology Biologics (KOBIO) registry (ClinicalTrials.gov, NCT01965132), a prospective nationwide biologics registry.Methods:We enrolled 1846 patients with AS in KOBIO registry and as disease controls, 471 patients with AS who did not take biologics in Kyungpook National University Hospital. The estimated glomerular filter rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation was evaluated in both groups. Renal insufficiency was defined as eGFR <60 mL/min/1.73 m2. Changes and differences of eGFR in each group were assessed at every follow-up year using paired t-test. Risk factors for renal function decline were identified using multivariable analysis.Results:The changes of eGFR values in patients treated with TNF inhibitors were not significantly decreased during 5 years follow up period. However, those in patients not treated with TNF inhibitors were significantly decreased. Moreover, among patients with renal insufficiency, use of TNF inhibitors did not affect further renal function deterioration during follow up period. Using multivariable logistic regression models, patients treated (versus not treated) with TNF inhibitors had a lower risk of renal function decline after 5 years follow up period (p<0.045).Conclusion:The use of TNF inhibitors was independently associated with lower risk of renal function decline and TNF inhibitors may be a safe treatment option in AS patients with renal insufficiency.Disclosure of Interests:None declared
Collapse
|
24
|
Chang SH, Lee JS, Lee JS, Park CH, Kim MU, Ha YJ, Kang EH, Lee YA, Park Y, Choe JY, Lee EY. POS0555 THE NATURAL COURSE OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE FOCUSING ON LUNG PHYSIOLOGY: A PROSPECTIVE OBSERVATIONAL COHORT STUDY (PART 1). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). However, there are few prospective studies for the natural course of lung physiology in most patients with RA-ILD.Objectives:To assess the natural course of lung physiology of RA-ILD and the relation between arthritis activity and pulmonary physiology in patients with RA-ILD.Methods:The KOrean Rheumatoid Arthritis ILd (KORAIL) cohort is the prospective observational cohort and aims to investigate the natural course of RAILD. Based on either 1987 or 2020 ACR criteria, patients diagnosed with RA and ILD based on CT scan were recruited from six tertiary medical hospitals in Korea since January 2015. RA disease activity was assessed using swollen and tender joint count by treating physician, inflammatory markers including CRP and ESR, and patient’s global assessment annually. Pulmonary function tests (PFT), including FVC, FEV1, DLCO, and chest CT scan, were conducted annually.Results:We analyzed 163 patients at baseline (V1), 141 at 1-year (V2), 122 at 2-year (V3), and 88 at 3-year follow-up (V4). The mean (±SD) duration since RA diagnosis and since ILD diagnosis was 7.6±8.0 and 2.7±3.1 years, respectively. The female to male ratio was about 2:1, and 58.9% of patients (n=96) were 65 years old or older. Only two patients were negative for RF and anti-CCP; 98.7% of patients (n=161/163) were positive for RF (n=143, 87.7%) or anti-CCP antibody (n=154, 94.5%). At enrollment, one-hundred-nine patients (66.9%) had FVC ≥80 % of predicted. Twenty-five patients (15.3%) showed FEV1/FVC≥0.7, of which seventeen patients, only ten percent of a total cohort (10.4%), had FVC ≥80% of predicted, which corresponds to the obstructive pattern. Proportion of patients showed a ≥10-point decline from the enrollment in FVC of the predicted value were around 10% at every year (Table 1). The proportion of patients with a relative decline of ≥10% from the enrollment in FVC predicted was increased every year because of cumulation. The proportion of patients with a relative decline of ≥10% from the previous visit in FVC predicted was also around 10-15% every year. Proportions of patients with 55% or more DLco % pred. has been decreased annually; 78.5% (n=128/158) at V1, 72.9% (n=105/139) at V2, 68.7% (n=90/117) at V3, and 56.6% (n=56/85) at V4. Patients with a relative decline of ≥10% from the enrollment in DLco predicted was 38 (27.5 %) at V2 and 37 (31.9%) at V3. Patients with a relative decline of ≥10% from the previous visit in DLco predicted was 29 (25.2%) at V3. Of note, thirty patients (21.7%) showed a relative 10% or more increase from enrollment in DLco predicted at V2, and so did 30 patients (25.9%) at V3.Table 1.The analysis of forced vital capacity (FVC) in KORIL cohortV1 (enrollment)V2 (1-year)V3 (2-year)V4 (3-year)FVC (mL), mean±SD2549.5 ± 743.32479.5±764.42435.8 ± 742.82405.7 ± 731.2FVC % of predicted, mean±SD84.70 ± 16.7484.7±18.184.3 ± 17.683.1 ± 19.1Rate of FVC decline, mL·year-1 (95% CI)--14 (-49, 21)-62 (-104, -21)-A 10-point decline from V1 in predicted FVC value, n (%)-10 (7.1)16 (13.3)8 (9.4)Relative decline of 10% from V1 in predicted FVC value, n (%)-17 (12.1)23 (18.9)17 (19.3)Relative decline of 10% from the previous visit in predicted FVC value, n (%)-17 (12.1)17 (14.2)13 (15.3)Conclusion:Annually, about 10-15% of patients experience a relative ≥10% decline from the previous visit in FVC predicted value in RA-ILD.Acknowledgements:This work was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant no.HI14C1277).Disclosure of Interests:None declared
Collapse
|
25
|
Chang SH, Lee JS, Lee JS, Park CH, Kim MU, Ha YJ, Kang EH, Lee YA, Park Y, Choe JY, Lee EY. POS0563 THE NATURAL COURSE OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE FOCUSING ON LUNG PHYSIOLOGY AND DISEASE ACTIVITY: A PROSPECTIVE COHORT STUDY (PART 2). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). However, the effect of RA disease activity on the course of ILD is not yet known.Objectives:To assess the natural course of lung physiology of RA-ILD and the relation between arthritis activity and pulmonary physiology in patients with RA-ILD.Methods:The Korean Rheumatoid Arthritis ILd (KORAIL) cohort is the prospective observational cohort and aims to investigate the natural course of RAILD. Based on either 1987 or 2020 ACR criteria, patients diagnosed with RA and ILD based on CT scan were recruited from six tertiary medical hospitals in Korea since January 2015. RA disease activity was assessed using disease activity (DAS)28-ESR and CRP, annually. Pulmonary function tests (PFT), including FVC and DLCO were conducted annually. According to the transition of DAS28-ESR status, we classified patients into four groups: Group A. persistent remission or low disease activity, Group B. improvement, Group C. worsening, Group D. persistent moderate to high disease activity.Results:We analyzed 143 patients who completed a 2-year follow-up (visit 2) or had died with available PFT results at least twice. Mean duration since RA diagnosis and since ILD diagnosis was 7.6±8.0 and 2.7±3.1 years, respectively. Twenty-four patients were Group A, 33 Group B, 10 Group C and 30 Group D. The mean of FVC (mL) and % of the predicted value in FVC was significantly lower in Group D than in other groups (Table 1). The annual rate of decline in FVC was -42 (95% CI -93~10) mL·year-1 in Group B while -113 (95% CI -206~-21) mL·year-1 in Group C (Figure 1A). The annual decline rate in Group C was further exaggerated in patients with ≥ 80% of FVC predicted (-141, 95% CI -251~-32 mL·year-1). During two years of follow-up, patients ever experienced a relative decline of ≥10% from the enrollment in FVC predicted was 27.3%(n-9/33) in Group B whereas 30.0% (3/10) in Group C. The annual rate of decline in % of DLco predicted value was also the largest in Group C (-4.6 %·year-1, 95%CI -8.5~-0.7), which further exaggerated in patients with ≥ 80% of FVC predicted (-4.9%·year-1, 95 %CI -8.3~-1.5, Figure 1B). Of note, about half of patients with maintained not only low disease activity (Group A) but also moderate to severe disease activity (Group D) improved in DLco at least 10% or more from the enrollment of DLco predicted value (Group A: 54.2%, n=13/24, Group D: 46.7%, n=14/30).Conclusion:RA disease activity is associated with the change of lung physiology in patients with RA-ILD; worsening disease activity associated with a further decrease of annual change in FVC and maintaining low disease activity associated with a further increase of annual change in % of DLco predicted value.Table 1.The analysis of forced vital capacity (FVC) according to disease activity transition group.Group AGroup BGroup CGroup DFVC (mL), mean±SD2810.0±771.12528.8±735.32801.0±952.72048.3±575.7FVC % of predicted, mean±SD87.5±14.586.5±16.693.0±15.677.2±17.3Rate of FVC decline, mL·year-1 (95% CI)-52 (-112,7)-42 (-93,10)-113 (-206, -21)1 (-52, 54)A 10-point decline from V1 in predicted FVC value, n (%)29 (20.3)6 (25.0)6 (18.2)3 (30.0)Relative decline of 10% from the enrollment in predicted FVC value, n (%)35 (24.5)5 (20.8)9 (27.3)3 (30.0)Figure 1.The annual change of pulmonary physiology according to disease activity transition group.Acknowledgements:This work was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant no.HI14C1277).Disclosure of Interests:None declared
Collapse
|
26
|
Chang SH, Lee JS, Lee JS, Park CH, Kim MU, Ha YJ, Kang EH, Lee YA, Park Y, Choe JY, Lee EY. POS0564 THE EFFECT OF ARTHRITIS TREATMENT ON THE COURSE OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE FOCUSING ON BIOLOGIC DMARDS: FROM A PROSPECTIVE COHORT STUDY (PART 5). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). However, the effect of RA treatment on the course of ILD is not yet known.Objectives:To assess the effect of RA treatment on the course of lung physiology of RA-focusing on biologic DMARDs treatment.Methods:The Korean Rheumatoid Arthritis ILd (KORAIL) cohort is the prospective observational cohort and aims to investigate the natural course of RAILD. Based on either 1987 or 2020 ACR criteria, patients diagnosed with RA and ILD based on CT scan were recruited from six tertiary medical hospitals in Korea since January 2015. RA disease activity was assessed using disease activity (DAS)28-ESR and CRP, annually. Pulmonary function tests (PFT), including FVC and DLCO were conducted annually. In the current study, we analyzed patients who completed a 2-years follow-up or had died during those terms till October 2020. They classified patients into three groups: patients treated with abatacept ≥24 weeks ever (Group 1), those with other bDAMRDs ≥24 weeks ever (Group 2), and those without any bDMARDs or with bDMARDs <24 weeks (Group 3).Results:Of a total of 125 patients who completed 2-year follow-up, 21 patients were classified as Group 1, 26 for Group 2, and 78 for Group 3. The mean age or the number of patients with ≥ 65-year-old was comparable between groups(Table 1). The mean duration since RA diagnosis was shorter in Group 3, but that since ILD diagnosis was comparable. DAS28-ESR score was comparable between Group 1 and 2 at enrollment, so was in 1-year-follow-up (p=0.75) and 2-year-follow-up (p=1.00). FVC and % of the predicted value in FVC, FEV1, and DLco were also comparable among the three groups at enrollment. The numbers of patients with ≥10-point decline in % of FVC predicted was 2 (10.0%) for Group 1, 1 (3.8%) for Group 2, 3 (3.9%) for Group3 during the first 1-year follow-up, and 3 (15.8%), 3 (11.5%), 10 (14.1%) during the last 1-year follow up. The percent of FVC predicted was 81.6 ± 17.5 %, 87.4 ± 17.9 %, 85.2 ± 17.7 % for Group 1,2 and 3, respectively, at 1-year-follow-up, and 79.5 ± 18.8 %, 89.0 ± 16.8 %, 83.5 ± 17.3 % at 2-year-follow-up. (Figure 1A). The percent of DLco predicted was 75.5 ± 23.4 %, 66.7 ± 18.1 %, 67.5 ± 16.7 % for Group 1,2 and 3, respectively, at 1-year-follow-up, and 74.0 ± 23.7 %, 69.1 ± 18.9 %, 67.0 ± 18.5 % at 1-year-follow-up (Figure 1B).Conclusion:Treatment of bDMARDs did not exacerbate FVC than without bDMARDs treatment and mitigated the decline of DLCO compared to without bDMARDs treatment during 2-year-follow-up.Table 1.Clinical characteristics at enrollment (V1)TotalGroup 1.Group 2.Group 3.PN125212678Age at enrollment65.9±8.266.0±8.863.9±8.066.6±8.10.3465, n (%)72 (57.6)13 (61.9)11 (42.3)48 (61.5)0.21Female, n (%)89 (71.2)16 (76.2)17 (65.4)56 (71.8)0.71RA duration, years8.0±8.49.6±6.69.2±9.07.2±8.60.05ILD duration, years3.0±3.33.8±3.73.8±3.52.5±3.10.10BMI, kg/m224.1±3.123.8±3.724.8±2.923.9±3.00.39Ever-smoker1855180.57RF positive, n (%)111 (88.8)19 (90.5)22 (84.6)70 (89.7)0.72Anti-CCP positive, n (%)119 (95.2)20 (95.2)25 (96.2)74 (94.9)1.00Arthritis activityDAS28-ESR4.0 ± 1.44.1 ± 1.14.3 ± 1.83.8 ± 1.40.60*DAS28-CRP3.1 ± 1.43.2 ± 1.23.4 ± 1.63.0 ± 1.40.76*HAQ-DI0.70 ± 0.760.64 ± 0.490.82 ± 0.820.67 ± 0.800.28*Pulmonary function testFVC, ml2522.5 ± 765.42406.2 ± 772.62617.3 ± 965.22522.2 ± 692.30.65FVC, % of pred.84.6 ± 16.980.9 ± 17.786.12 ± 17.8285.08 ± 16.50.53FEV1, % of pred.92.4 ± 21.492.0 ± 24.890.6 ± 22.193.0 ± 20.40.88DLco, % of pred.71.5 ± 19.772.3 ± 26.769.1 ± 16.472.0 ± 18.70.80Figure 1.Acknowledgements:This research was supported by Bristol Myers Squibb Inc.Disclosure of Interests:Sung Hae Chang: None declared, Ji Sung Lee: None declared, Jeong Seok Lee: None declared, Chan Ho Park: None declared, Min Uk Kim: None declared, You-Jung Ha: None declared, Eun Ha Kang: None declared, Yeon Ah Lee: None declared, Yongbeom Park: None declared, Jung-Yoon Choe: None declared, Eun Young Lee Grant/research support from: Bristol Myers Squibb Inc.
Collapse
|
27
|
Lee J, Kwon OS, Lee JS, Yu HT, Kim TH, Uhm JS, Joung BY, Lee MH, Pak HN. Left atrial wall stress and the outcome of catheter ablation for atrial fibrillation: artificial intelligence-based prediction of clinical outcome. Europace 2021. [DOI: 10.1093/europace/euab116.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background/Introduction: Left atrial (LA) wall stress (LAW-str) may contribute to the mechanism of atrial fibrillation (AF).
Purpose
We explored the clinical characteristics and the rhythm outcome of AF depending on LAW-str among the patients who underwent AF catheter ablation (AFCA). We also tested whether artificial intelligence (AI) properly estimate LAW-str without invasive parameters.
Methods
We included 2223 patients (72.8% male, 59.0 [52.0–67.0] years old, 28.7% with persistent AF [PeAF]) who underwent radiofrequency catheter ablation (RFCA). LAW-str was calculated by the Law of Laplace using LA diameter (echocardiogram), peak LA pressure, and mean LA wall thickness (computed tomography) measured by customized software. Based on the quartile (Q1–4) or AI-estimated values of LAW-str, we compared clinical characteristics and rhythm outcome.
Results
LAW-str was independently associated with PeAF (p < 0.001), diabetes (p = 0.012) and vascular disease (p = 0.002), body mass index (p < 0.001), E/Em (p < 0.001), and mean LA voltage (p < 0.001). During 26.0 (12.0–52.0) months follow-up, clinical recurrence of AF was significantly higher in the Q4 of LAW-str group (log rank p = 0.001). LAW-str was independently associated with clinical recurrence after AFCA (HR 1.001 [1.000–1.002], p = 0.013). AI-based model using non-invasive parameters predicted Q4 of LAW-str with area under the curve (AUC) 0.734, which was similar to logistic regression based predictive model using all data including invasive parameters (AUC 0.726). Patients in Q4 of LAW-str showed consistently worse rhythm outcome regardless of the type of AF, sex, or AI-based prediction (p = 0.039).
Conclusions
The LAW-str seems to be associated with rhythm outcome of AFCA and AI can predict this complex parameter with moderate accuracy. TableMultivariateβ (95% CI)PPersistent AF31.08 (21.77-40.39)<0.001Diabetes mellitus15.36 (3.35-27.38)0.012Vascular disease22.27 (8.4-36.14)0.002Body mass index2.91 (1.53-4.29)<0.001E/Em4.95 (3.87-6.02)<0.001Mean LA voltage-22.24 (-27.96–16.52)<0.001Linear regression analysis for clinical variables predictive of LA wall stress (10^3 dyn/cm2).Abstract Figure. AF recurrence by LAW-str, AI-prediction
Collapse
Affiliation(s)
- J Lee
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - OS Kwon
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - JS Lee
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - HT Yu
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - TH Kim
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - JS Uhm
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - BY Joung
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - MH Lee
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - HN Pak
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| |
Collapse
|
28
|
Pendharkar M, Zhang B, Wu H, Zarassi A, Zhang P, Dempsey CP, Lee JS, Harrington SD, Badawy G, Gazibegovic S, Op Het Veld RLM, Rossi M, Jung J, Chen AH, Verheijen MA, Hocevar M, Bakkers EPAM, Palmstrøm CJ, Frolov SM. Parity-preserving and magnetic field-resilient superconductivity in InSb nanowires with Sn shells. Science 2021; 372:508-511. [PMID: 33858990 DOI: 10.1126/science.aba5211] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 03/13/2021] [Indexed: 11/02/2022]
Abstract
Improving materials used to make qubits is crucial to further progress in quantum information processing. Of particular interest are semiconductor-superconductor heterostructures that are expected to form the basis of topological quantum computing. We grew semiconductor indium antimonide nanowires that were coated with shells of tin of uniform thickness. No interdiffusion was observed at the interface between Sn and InSb. Tunnel junctions were prepared by in situ shadowing. Despite the lack of lattice matching between Sn and InSb, a 15-nanometer-thick shell of tin was found to induce a hard superconducting gap, with superconductivity persisting in magnetic field up to 4 teslas. A small island of Sn-InSb exhibits the two-electron charging effect. These findings suggest a less restrictive approach to fabricating superconducting and topological quantum circuits.
Collapse
Affiliation(s)
- M Pendharkar
- Electrical and Computer Engineering, University of California, Santa Barbara, CA 93106, USA
| | - B Zhang
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - H Wu
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - A Zarassi
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - P Zhang
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - C P Dempsey
- Electrical and Computer Engineering, University of California, Santa Barbara, CA 93106, USA
| | - J S Lee
- California NanoSystems Institute, University of California, Santa Barbara, CA 93106, USA
| | - S D Harrington
- Materials Department, University of California, Santa Barbara, CA 93106, USA
| | - G Badawy
- Eindhoven University of Technology, 5600 MB Eindhoven, Netherlands
| | - S Gazibegovic
- Eindhoven University of Technology, 5600 MB Eindhoven, Netherlands
| | | | - M Rossi
- Eindhoven University of Technology, 5600 MB Eindhoven, Netherlands
| | - J Jung
- Eindhoven University of Technology, 5600 MB Eindhoven, Netherlands
| | - A-H Chen
- Univ. Grenoble Alpes, CNRS, Grenoble INP, Institut Néel, 38000 Grenoble, France
| | - M A Verheijen
- Eindhoven University of Technology, 5600 MB Eindhoven, Netherlands
| | - M Hocevar
- Univ. Grenoble Alpes, CNRS, Grenoble INP, Institut Néel, 38000 Grenoble, France
| | - E P A M Bakkers
- Eindhoven University of Technology, 5600 MB Eindhoven, Netherlands
| | - C J Palmstrøm
- Electrical and Computer Engineering, University of California, Santa Barbara, CA 93106, USA.,California NanoSystems Institute, University of California, Santa Barbara, CA 93106, USA.,Materials Department, University of California, Santa Barbara, CA 93106, USA
| | - S M Frolov
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, PA 15260, USA.
| |
Collapse
|
29
|
Kang J, Oh YM, Lee JH, Kim EK, Lim SY, Kim WJ, Yoon HI, Kim TH, Park TS, Kim SO, Lee SW, Lee SD, Lee JS. Distinctive patterns of pulmonary function change according to baseline lung volume and diffusing capacity. Int J Tuberc Lung Dis 2021; 24:597-605. [PMID: 32553011 DOI: 10.5588/ijtld.19.0401] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
SETTING: Multicentre retrospective study in South Korea.OBJECTIVE: To longitudinally evaluate changes in lung volume and diffusing capacity for carbon monoxide (DLCO) with forced expiratory volume in 1 sec (FEV1).DESIGN: A total of 155 patients with chronic obstructive pulmonary disease (COPD), whose pulmonary function parameters were measured annually for 5 years, were selected from a prospective cohort in South Korea. A random coefficients model was used to estimate mean annual FEV1, lung volume parameter and DLCO change rates.RESULTS: Patients were classified into four groups based on baseline DLCO and residual volume/total lung capacity (RV/TLC) measurements. The annual FEV1 decline rate was greater in patients with low DLCO than in those with normal DLCO, with the greatest decline occurring in patients with low DLCO and normal RV/TLC. RV and RV/TLC declined in patients with high RV/TLC, whereas these increased in patients with normal RV/TLC. DLCO decreased longitudinally in all four groups, with the greatest decline occurring in patients with normal DLCO and normal RV/TLC.CONCLUSIONS: Different subgroups of patients with COPD exhibited distinctive pulmonary function change patterns. Baseline DLCO and RV/TLC may be used as physiological markers to predict long-term changes in pulmonary function.
Collapse
Affiliation(s)
- J Kang
- Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul
| | - Y-M Oh
- Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul
| | - J-H Lee
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bundang CHA Hospital, College of Medicine, CHA University, Seongnam
| | - E K Kim
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bundang CHA Hospital, College of Medicine, CHA University, Seongnam
| | - S Y Lim
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul
| | - W J Kim
- Department of Internal Medicine, College of Medicine, Kangwon National University, Chuncheon
| | - H I Yoon
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam
| | - T-H Kim
- Division of Pulmonology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri
| | - T S Park
- Division of Pulmonology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri
| | - S O Kim
- Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, Seoul, South Korea
| | - S W Lee
- Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul
| | - S-D Lee
- Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul
| | - J S Lee
- Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul
| |
Collapse
|
30
|
Jahurul MHA, Shian OK, Sharifudin MS, Hasmadi M, Lee JS, Mansoor AH, Jumardi R, Khan MF, Jinap S, Omar AKM, Zaidul ISM. Effects of drying methods on oxidative stability of roselle seed oil ( Hibiscus Sabdariffa): an optimization approach. J Food Sci Technol 2021; 58:902-910. [PMID: 33678873 PMCID: PMC7884491 DOI: 10.1007/s13197-020-04604-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Revised: 04/17/2020] [Accepted: 06/19/2020] [Indexed: 06/12/2023]
Abstract
The objective of this study was to optimize the extraction of oil from pre-dried roselle seeds using response surface methodology (RSM). We also determined the oxidative stability of oil extracted from oven and freeze-dried roselle seed in terms of iodine value (IV), free fatty acid (FFA) value, peroxide value (PV), P-anisidine and total oxidation values (TOTOX value). The RSM was designated based on the central composite design with the usage of three optimum parameters ranged from 8 to 16 g of sample weight, 250-350 mL of solvent volume, and 6-8 h of extraction time. The highest oil yielded from roselle seed using the optimization process was 22.11% with the parameters at sample weight of 14.4 g, solvent volume of 329.70 mL, and extraction time of 7.6 h. Besides, the oil extracted from the oven dried roselle seed had the values of 89.04, 2.11, 4.13, 3.76 and 12.03 for IV, FFA, PV, P-anisidine, and TOTOX values, respectively. While for the oil extracted from freeze-dried roselle seed showed IV of 90.31, FFA of 1.64, PV of 2.47, P-anisidine value of 3.48, and TOTOX value of 8.42. PV and TOTOX values showed significant differences whereas; IV, FFA, and P-anisidine values showed no significant differences between the oven and freeze-dried roselle seed oils.
Collapse
Affiliation(s)
- M. H. A. Jahurul
- Faculty of Food Science and Nutrition, Universiti Malaysia Sabah, 88400 Kota Kinabalu, Sabah Malaysia
| | - O. K. Shian
- Faculty of Food Science and Nutrition, Universiti Malaysia Sabah, 88400 Kota Kinabalu, Sabah Malaysia
| | - M. S. Sharifudin
- Faculty of Food Science and Nutrition, Universiti Malaysia Sabah, 88400 Kota Kinabalu, Sabah Malaysia
| | - M. Hasmadi
- Faculty of Food Science and Nutrition, Universiti Malaysia Sabah, 88400 Kota Kinabalu, Sabah Malaysia
| | - J. S. Lee
- Faculty of Food Science and Nutrition, Universiti Malaysia Sabah, 88400 Kota Kinabalu, Sabah Malaysia
| | - A. H. Mansoor
- Faculty of Food Science and Nutrition, Universiti Malaysia Sabah, 88400 Kota Kinabalu, Sabah Malaysia
| | - R. Jumardi
- Faculty of Food Science and Nutrition, Universiti Malaysia Sabah, 88400 Kota Kinabalu, Sabah Malaysia
| | - M. Firoz Khan
- Department of Chemistry, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia
| | - S. Jinap
- Department of Food Science, Faculty of Food Science and Technology, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor Malaysia
- Food Safety and Food Integrity (FOSFI), Institute of Tropical Agriculture and Food Security, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor Malaysia
| | - A. K. Mohd Omar
- School of Industrial Technology, Universiti Sains Malaysia, 11800 Minden, Penang Malaysia
| | - I. S. M. Zaidul
- Faculty of Pharmacy, International Islamic University Malaysia, Kuantan Campus, 25200 Pahang, Malaysia
| |
Collapse
|
31
|
Lee JS, Schwaiger B, Eszlari E, Eichinger W. Impact of COVID-19 Lockdown on Adult Cardiac Surgery in a Public Hospital. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Safren SA, Harkness A, Lee JS, Rogers BG, Mendez NA, Magidson JF, Blashill AJ, Bainter S, Rodriguez A, Ironson G. Addressing Syndemics and Self-care in Individuals with Uncontrolled HIV: An Open Trial of a Transdiagnostic Treatment. AIDS Behav 2020; 24:3264-3278. [PMID: 32410049 PMCID: PMC7546114 DOI: 10.1007/s10461-020-02900-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Interventions addressing syndemics and ART adherence are needed for individuals with uncontrolled HIV and psychosocial problems. Twenty-seven participants with detectable HIV plasma viral load (PVL) or recent STI participated in an open trial of transdiagnostic adherence counseling and cognitive behavioral therapy. Outcomes were collected at baseline, 4-, and 8-months. Log PVL improved from baseline to 4-month (γ = - 1.13, 95% CI - 1.72, - 0.55, p < 0.001) and 8-month (γ = - 0.93, 95% CI - 1.57, - 0.30, p = 0.006), with more participants suppressed at 4- (χ2(1) = 9.09, p = 0.001) and 8-month (χ2(1) = 5.14, p = 0.016). Self-reported adherence improved across major assessments (γ = 0.87, 95% CI 0.28, 1.46, p = .005); Wisepill adherence did not. Negative affect declined during treatment (γ = - 0.28, 95% CI - 0.40, - 0.16, p < 0.001), with improvement at 4- (γ = - 4.34, 95% CI - 6.99, - 1.69, p = 0.002) but not 8-month. Positive affect trended positively during treatment and from baseline to 4-month, with significant 8-month improvement (γ = 3.84, 95% CI 0.33, 7.44, p = 0.04). Depressive symptoms did not change. In a complicated sample of participants selected for uncontrolled HIV, the intervention yielded improved PVL and self-reported adherence. Efforts to end HIV should improve upon strategies such as these, addressing syndemics. Registration: clinicaltrial.gov: NCT02696681.
Collapse
Affiliation(s)
- S A Safren
- Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., P.O. Box 248185, Coral Gables, FL, 33124, USA.
| | - A Harkness
- Department of Public Health Sciences, University of Miami, Miami, FL, USA
| | - J S Lee
- Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., P.O. Box 248185, Coral Gables, FL, 33124, USA
| | - B G Rogers
- Department of Medicine, Brown University, Providence, RI, USA
| | - N A Mendez
- Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., P.O. Box 248185, Coral Gables, FL, 33124, USA
| | - J F Magidson
- Department of Psychology, University of Maryland, College Park, MD, USA
| | - A J Blashill
- Department of Psychology, San Diego State University, San Diego, CA, USA
| | - S Bainter
- Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., P.O. Box 248185, Coral Gables, FL, 33124, USA
| | - A Rodriguez
- Department of Medicine, University of Miami, Miami, FL, USA
| | - G Ironson
- Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., P.O. Box 248185, Coral Gables, FL, 33124, USA
| |
Collapse
|
33
|
Park D, Goh CJ, Lee JS, Sebastiani F, Hahn Y. Identification of Pistacia-associated flexivirus 1, a putative mycovirus of the family Gammaflexiviridae, in the mastic tree (Pistacia lentiscus) transcriptome. Acta Virol 2020; 64:28-35. [PMID: 32180416 DOI: 10.4149/av_2020_104] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In this study, we identified the genome sequence of the novel virus Pistacia-associated flexivirus 1 (PAFV1), a putative member of the mycovirus family Gammaflexiviridae (the order Tymovirales), via analysis of a transcriptome dataset for the mastic tree (Pistacia lentiscus, the family Anacardiaceae). PAFV1 was predicted to have three open reading frames (ORFs): ORF1, encoding a replicase (REP) with RNA-dependent RNA polymerase activity; ORF2, a movement protein (MP); and ORF3, a hypothetical protein. The PAFV1 REP sequence showed high similarity to those of three known members of the family Gammaflexiviridae i.e., Entoleuca gammaflexivirus 1 (EnFV1), Entoleuca gammaflexivirus 2 (EnFV2), and Botrytis virus F (BVF). A genome contig of the fungus Monosporascus cannonballus also contained a sequence of an endogenous virus similar to that of PAFV1. Sequence comparison and phylogenetic analysis indicated that PAFV1, EnFV1, and the endogenous virus of M. cannonballus formed a distinct subgroup (apart from EnFV2 and BVF), and may be the founding members of a novel genus in the family Gammaflexiviridae. Notably, MP sequences of PAFV1/EnFV1 showed similarity to the MP sequences of the mycovirus group called tobamo-like mycoviruses (an unassigned taxon), implying that genomic recombination occurred between members of the family Gammaflexiviridae and tobamo-like mycoviruses. Since PAFV1 is phylogenetically related to mycoviruses, PAFV1 may also be a mycovirus that infected a fungus associated with the mastic tree sample, which is evidenced by the presence of fungal ribosomal RNA sequences in the mastic tree transcriptome. Thus, the PAFV1 genome sequence may be useful in elucidating the genome evolution of Gammaflexiviridae and tobamo-like mycoviruses. Keywords: Pistacia-associated flexivirus 1; Gammaflexiviridae; mycovirus, mastic tree.
Collapse
|
34
|
Stewart KT, Lee JS, Pan K, Albert AY, Fisher S. Outcome of using vaginal misoprostol for treatment of retained products of conception after first trimester miscarriage: a retrospective cohort study. EUR J CONTRACEP REPR 2020; 25:474-479. [PMID: 32869658 DOI: 10.1080/13625187.2020.1807498] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
PURPOSE Standard treatment for retained products of conception (RPOC) is dilation and curettage (D&C), however, this brings a risk of intrauterine synechiae and subsequent fertility issues. A treatment strategy to avoid D&C is medical management with misoprostol. The justification for misoprostol in this setting is extrapolated from miscarriage and termination literature, however, no studies have looked specifically in the setting of RPOC. The purpose of this study is to determine the efficacy of misoprostol as definitive management of RPOC. MATERIALS AND METHODS A retrospective cohort study was conducted from January 2016 to March 2017 at an Early Pregnancy Assessment Clinic. Patients diagnosed with RPOC with clinical symptoms and ultrasound findings of endometrial mass and/or doppler flow treated expectantly, medically with vaginal misoprostol or with a suction D&C underwent a chart review. Primary outcome was resolution of RPOC without surgical intervention. RESULTS AND CONCLUSIONS Of 1743 unique pregnancies, 189 women were diagnosed with RPOC. 34% (65/178) chose misoprostol for management of RPOC. Baseline demographics between the three treatment modalities (expectant, medical, surgical) were comparable. 65% (42/65) of patients who took misoprostol avoided D&C. Misoprostol is most effective (76%) in the setting of RPOC if the primary treatment for miscarriage was expectant management, with less success with primary medical management (44%) and primary surgical management (40%).
Collapse
Affiliation(s)
- K T Stewart
- Division of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
| | - J S Lee
- Division of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.,Saskatchewan Cancer Agency, Regina, Canada
| | - K Pan
- Division of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
| | - A Y Albert
- Women's Health Research Institute, BC Women's Hospital, Vancouver, Canada
| | - S Fisher
- Division of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
| |
Collapse
|
35
|
Lee JS, Kim EH, Lee SH. Endoscopically assisted malarplasty: L-rotation technique. J Stomatol Oral Maxillofac Surg 2020; 122:229-234. [PMID: 32810601 DOI: 10.1016/j.jormas.2020.07.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 06/21/2020] [Accepted: 07/28/2020] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Endoscopically assisted malarplasty with a greenstick fracture is a method for preserving the body eminence and improving arch protrusion. However, this technique is inadequate when malar body reduction is required. To compensate for these limitations, we developed a new surgical technique using the endoscope to reduce body protrusion. MATERIAL AND METHODS We enrolled 261 patients who visited our clinic for zygoma reduction from January 2017 to December 2018. Their mean age was 31 (range 17-63) years. After a scalp incision, an incomplete osteotomy was created from the most prominent portion of the zygoma body to the zygomaticomaxillary suture line. A complete osteotomy was performed on the arch. These osteotomies resulted in an L-shaped zygoma segment after tapping the bone with a mallet. RESULTS Of the 261 patients who underwent our L-rotation technique, 242 also received a corticotomy. Of those patients, 15 underwent a different degree of zygoma reduction on both sides. A floating zygomatic segment occurred in four cases, although no further surgery was required. One patient's zygomatic segment dropped on one side, requiring rigid fixation through the intraoral approach. Most patients were satisfied and there were no specific complications. CONCLUSIONS Endoscopically assisted malarplasty using an L-rotation technique enables the protrusion of both the arch and body to be reduced. The zygoma reduction can be modified based on the location of the incomplete osteotomoy line and the number of corticotomies required.
Collapse
Affiliation(s)
- J S Lee
- Youtiful Vom Aesthetic Plastic Clinic, 326 Dosan-daero, Gangnam-gu, Seoul, Republic of Korea
| | - E H Kim
- Inje University Ilsan Paik Hospital, 170 Juhwa-ro, Goyang-si, Gyeonggi-do, Republic of Korea
| | - S H Lee
- Inje University Ilsan Paik Hospital, 170 Juhwa-ro, Goyang-si, Gyeonggi-do, Republic of Korea.
| |
Collapse
|
36
|
Andersen LS, Joska JA, Magidson JF, O'Cleirigh C, Lee JS, Kagee A, Witten JA, Safren SA. Detecting Depression in People Living with HIV in South Africa: The Factor Structure and Convergent Validity of the South African Depression Scale (SADS). AIDS Behav 2020; 24:2282-2289. [PMID: 31965430 PMCID: PMC8021389 DOI: 10.1007/s10461-020-02787-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Screening measures for depression developed in high-income countries have not always demonstrated strong psychometric properties in South Africa and with people living with HIV (PLWH). The present study explored the psychometric properties of the 16-item South African Depression Scale (SADS) comprised of idioms of distress specific to isiXhosa culture in PLWH. The SADS was administered to 137 Xhosa-speaking PLWH who met diagnostic criteria for major depressive disorder (MDD) together with the Hamilton Depression Scale (HAM-D) and the Center for Epidemiological Studies Depression Scale (CES-D). We conducted exploratory factor analysis, correlation, and reliability statistics. Four factors of the SADS emerged: Sadness, lethargy/burdened, anhedonia/withdrawal, and cognitive/somatic. All factors correlated significantly with the HAM-D and CES-D. Internal consistency of the overall measure was high (α = .89). The SADS promises to be a robust measure of depression in isiXhosa-speaking PLWH in South Africa likely due to the inclusion of local idioms of distress.
Collapse
Affiliation(s)
- L S Andersen
- HIV Mental Health Research Unit, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
| | - J A Joska
- HIV Mental Health Research Unit, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa
| | - J F Magidson
- Department of Psychology, University of Maryland, College Park, MA, USA
| | - C O'Cleirigh
- Behavioral Medicine Service, Massachusetts General Hospital/Department of Psychiatry, Harvard Medical School, Boston, MA, USA
| | - J S Lee
- Department of Psychology, University of Miami, Florida, USA
| | - A Kagee
- Department of Psychology, Stellenbosch University, Western Cape, South Africa
| | - J A Witten
- HIV Mental Health Research Unit, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa
| | - S A Safren
- Department of Psychology, University of Miami, Florida, USA
| |
Collapse
|
37
|
Jeon YJ, Han YJ, Choi MH, Lee JS, Lee JH, Jo SH, Kim SH. Mental health states and influencing factors of risky and problem drinking in South Korean female adolescents. Public Health 2020; 185:61-69. [PMID: 32570147 DOI: 10.1016/j.puhe.2020.04.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 04/12/2020] [Accepted: 04/21/2020] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Alcohol is one of the most used and abused psychoactive substances by adolescents. We investigated influencing factors of risky and problem drinking in Korean female adolescents. STUDY DESIGN The study design used is a cross-sectional modeling. METHODS We used data from the 13th Korean Youth Risk Behavior Web-based Survey (KYRBS) conducted in 2017. KYRBS data were obtained from a stratified, multistage, clustered sample. Risky drinking was binge drinking and problem drinking was drinking with several conflicts association with alcohol consumption. RESULTS Among 62,276 participants, the rates of current, risky, and problem drinking among all participants were 16.1%, 8.3%, and 6.1%, respectively. Although all of these rates were higher in males, risky and problem drinking rates among current female drinkers were higher than those of males (55.4 vs 48.5%, 38.9 vs 37.2%, respectively). Problem drinking was most strongly associated with risky drinking (adjusted odds ratio: 17.53 [95% confidence interval: 14.63-21.00]), similarly, risky drinking was most strongly associated with problem drinking in female current drinkers (17.76 [14.84-21.27]). Current smoking was the second strongest risk factor for risky and problem drinking in females (5.22 [3.92-6.95] and 2.93 [2.21-3.89], respectively). CONCLUSION Many female adolescents in Korea drink alcohol in an unhealthy manner. The female risky and problem drinking rates among current drinkers were higher than those of males. Risky drinking and problem drinking was most significant influencing factor among females, reciprocally. Public education on abstinence in female adolescents is warranted.
Collapse
Affiliation(s)
- Y J Jeon
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - Y J Han
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - M H Choi
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - J S Lee
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - J H Lee
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - S H Jo
- Department of Biostatstics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - S H Kim
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
| |
Collapse
|
38
|
Miyawaki A, Lee JS, Kobayashi Y. Impact of the school lunch program on overweight and obesity among junior high school students: a nationwide study in Japan. J Public Health (Oxf) 2020; 41:362-370. [PMID: 29873776 PMCID: PMC6636685 DOI: 10.1093/pubmed/fdy095] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2017] [Revised: 04/07/2018] [Accepted: 05/14/2018] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Japan has experienced a low prevalence of childhood obesity. The Japanese nationwide school lunch program is suggested to have helped this phenomenon, but it has not been proven. METHODS From official statistics, we combined annual data for 2006-15 about the prefecture-level school lunch coverage rate for public junior high school students and the prefecture-level nutritional indicators calculated by randomly selected age-sex groups of 13-15-year olds: the percentage of overweight, obese or underweight children, who are 20% heavier, 30% heavier or 20% lighter than the standard weight by sex, age and height; and mean body weight (kg) or height (cm). We estimated the impact of the school lunch coverage rate on the nutritional indicators in subsequent years, adjusting for the lagged dependent variable and dummies for prefecture, age and year. RESULTS A 10 percentage point increase in the prefecture-level school lunch coverage rate significantly decreased the percentage of overweight (0.37%, 95% CI: 0.18-0.56) and obesity (0.23%, 0.10-0.37) in subsequent years among boys, but not among girls. No significant effect on the percentage of underweight or mean body weight/height was observed for either sex. CONCLUSIONS Appropriate nutritional intake through school lunch may be effective to reduce childhood obesity.
Collapse
Affiliation(s)
- A Miyawaki
- Department of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - J S Lee
- Department of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - Y Kobayashi
- Department of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| |
Collapse
|
39
|
Nam SH, Lee JS, Choi SJ, Seo WJ, Oh JS, Hong S, Kim YG, Lee CK, Yoo B. AB0212 FLARE RISK AFTER DISCONTINUING LONG-TERM METHOTREXATE TREATMENT IN PATIENTS HAVING RHEUMATOID ARTHRITIS WITH LOW DISEASE ACTIVITY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Several recent studies have reported that MTX could be discontinued in patients with low disease activity who are taking biologic DMARDs or tofacitinib. However, there are limited studies on whether MTX could be discontinued in patients with low disease activity who have taken MTX for a long term.Objectives:We investigated the disease flare rate in patients with rheumatoid arthritis (RA) who achieved low disease activity following long-term methotrexate (MTX) treatment and the factors related to flare.Methods:This retrospective longitudinal cohort study included patients with RA and low disease activity who were exposed to MTX for >10 years. Disease flare was defined as an increase in DAS28 of >1.2 within 6 months of discontinuation of MTX. Logistic regression analysis was performed to identify the factors associated with flare.Results:In total, 97 patients with RA were included in the study. The mean baseline DAS28 was 1.96 ± 0.56. The median cumulative MTX dose was 11.7g; the median duration of exposure to MTX was 19 years. Following MTX discontinuation, flare occurred in 43 (44.3%) patients; the mean time to flare was 98 ± 37.7 days. According to univariable logistic regression analysis, C-reactive protein, erythrocyte sedimentation rate (ESR) at discontinuation, the average ESR in the 6 months before discontinuation of MTX, a weekly dose of MTX before discontinuation, and use of other conventional synthetic DMARDs were associated with a higher risk of disease flare. In multivariable analysis, a weekly dose of MTX before discontinuation (OR, 1.014; 95% CI, 1.014–1.342; p = 0.031) was significantly associated with flare risk.Conclusion:Among patients with RA who achieved low disease activity with long-term treatment with MTX, more than half of the patients remained flare free after MTX discontinuation. A higher MTX dose before discontinuation was associated with a high flare risk.Disclosure of Interests:None declared
Collapse
|
40
|
Choi SJ, Lee JS, Nam SH, Seo WJ, Oh JS, Hong S, Kim YG, Lee CK, Yoo B. FRI0118 RISK OF LIVER FIBROSIS ON TRANSIENT ELASTOGRAPHY IN PATIENTS WITH RHEUMATIC DISEASE UNDER LONG-TERM METHOTREXATE TREATMENT. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Methotrexate (MTX) is a cornerstone drug for the treatment of rheumatic disease and low doses of MTX are both tolerable and safe, with monitored toxicity, assessed via the liver function test. However, there is still controversy regarding the risk of liver fibrosis with long-term use of MTX. Transient elastography is commonly used to assess and monitor fibrosis progression in patients with chronic liver disease.Objectives:The present study aims to investigate liver fibrosis using transient elastography and related factors in patients with rheumatic disease receiving long-term MTX.Methods:The present retrospective, longitudinal, cross-sectional study included patients with an autoimmune disease who are taking cumulative MTX dosed over 7 g, and who had liver fibrosis upon examination using transient elastography. Liver fibrosis was defined as liver stiffness, valued over 7.2 kPa. Logistic regression analysis was performed to identify factors associated with liver fibrosis, and receiver operating characteristics analysis was used to determine the predictive value of each factor.Results:We included 83 patients with autoimmune disease, with a median MTX cumulative dose of 11.6 (range 7.3-16.0) g. Sixty-eight patients (81.9%) had rheumatoid arthritis (RA), and 13 patients (15.7%) had Takayasu arteritis. The median MTX exposure duration was 18 (range 9-31) years. The median liver stiffness value was 4 (range 1.8-10.2) kPa. Five patients (6%) showed liver fibrosis (3 patients; RA, 2 patients; Takayasu arteritis). In the linear regression analysis, cumulative MTX dose showed a tendency towards a positive correlation with increasing liver stiffness value (r2 =0.039, p = 0.074). In the logistic regression analysis, cumulative MTX dose was associated with a higher risk of liver fibrosis (OR: 1.734, 95% CI: 1.060–2.837, p = 0.029). In addition, cumulative MTX dose had an area under the curve (AUC) of 0.813 (95% CI 0.695-0.930) and a sensitivity of 80% and specificity of 71.8% at a cut-off value of 12.7 g.Conclusion:Liver fibrosis was observed in 6% of patients with long-term MTX use and higher cumulative MTX doses increased the risk of liver fibrosis. Thus, transient elastography should be considered in patients exposed to high cumulative doses of MTX.Disclosure of Interests:None declared
Collapse
|
41
|
Nam SH, Choi SJ, Lee JS, Oh JS, Hong S, Seo WJ, Lee CK, Yoo B, Kim YG. THU0210 EARLY DISCONTINUATION OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS CO-TREATED WITH RIFAMPIN FOR LATENT TUBERCULOSIS: RESULTS FROM THE REAL-WORLD DATA. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Rheumatoid arthritis (RA) patients need to undergo screening and receive treatment for latent tuberculosis infection (LTBI) before starting tofacitinib, which is primarily metabolized by cytochrome P450 (CYP) 3A4. Among chemoprophylactic agents, rifampin is known to be a potent CYP3A4 inducer; therefore, it is expected to decrease the efficacy of tofacitinib. However, tofacitinib and rifampin have been co-administered practically because of the short duration of chemoprophylaxis.Objectives:The aim of this study was to determine the efficacy of tofacitinib on co-administration with rifampin.Methods:Biologic-naïve RA patients treated with tofacitinib were selected, and electronic medical reports were reviewed retrospectively. All patients underwent screening for LTBI before starting tofacitinib, and patients with positive results were treated to prevent progression to active tuberculosis. To evaluate the efficacy of tofacitinib with or without rifampin, the discontinuation rates of tofacitinib were examined during the first 6 months. Kaplan–Meier analysis was used to construct cumulative discontinuation curves, and comparisons were performed using the log-rank test.Results:Among 81 patients who started tofacitinib, 21 (25.9%) were LTBI-positive and 18 (22.2%) were administered rifampin concomitantly with tofacitinib. The median follow-up time was 6 months in both patients who received rifampin (interquartile range [IQR] 2.21, 6.00) and those who did not receive rifampin (IQR 5.97, 6.00) (p = 0.083). There were no significant differences between patients who received rifampin and those who did not receive rifampin in all baseline characteristics, except the swollen joint count (3.00 [1.75, 5.25] vs. 5.00 [4.00, 7.00]; p = 0.025), at the time of starting tofacitinib. In patients who received rifampin at the time of starting tofacitinib, the mean duration of co-administration was 47.00 ± 23.54 days (median 56; IQR 28.75, 59.00). During follow-up, 14 of the 81 patients (17.3%) discontinued tofacitinib. As shown in the Figures 1 and 2, the discontinuation rate of tofacitinib within the first 6 months was significantly higher among patients who received rifampin for LTBI than among those who did not receive rifampin (lack of efficacy: 24.7% vs. 5.1%, p = 0.008; all causes: 38.9% vs. 11.2%, p = 0.002). Seven patients discontinued tofacitinib because of uncontrolled RA activity, and rifampin had been administered concomitantly in four of these seven patients. Of the four patients, three stopped taking tofacitinib in the middle of LTBI treatment, and the DAS28-ESR scores of these patients were higher at discontinuation than at baseline.Conclusion:Discontinuation rates were higher in RA patients who started tofacitinib during chemoprophylaxis involving rifampin than in those who did not receive rifampin. Physicians should be aware that the efficacy of tofacitinib could be decreased by the chemoprophylactic regimen for tuberculosis.Disclosure of Interests:None declared
Collapse
|
42
|
Choi SJ, Nam SH, Lee JS, Seo WJ, Oh JS, Hong S, Lee CK, Yoo B, Kim YG. AB1018 TREATMENT RESPONSE OF HYDRONEPHROSIS ASSOCIATED WITH IDIOPATHIC RETROPERITONEAL FIBROSIS, FOCUSING ON RATIO OF IgG4/IgG3 SERUM CONCENTRATION. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Hydronephrosis, a common complication of idiopathic retroperitoneal fibrosis (iRPF), may lead to poor renal outcomes unless it is resolved. Pathological confirmation can help to identify the aetiology of the disease and determine the treatment strategy. But, in most cases, it is difficult to obtain sufficient tissue due to the location of fibrosis. In a recent study, parts of iRPF are correlated with IgG4-related disease characterised by elevated serum IgG4 levels (>135 mg/dL). Normal serum IgG3 level (21–176 mg/dL) has been known to be higher than normal serum IgG4 level (4–86 mg/dL). The reverse IgG4/IgG3 ratio has been suggested to be an IgG4-related disease component that distinguishes it from primary sclerosing cholangitis [1]. However, the ratio of IgG3 and IgG4 may be reversed in iRPF patients with hydronephrosis.Objectives:We aimed to investigate the ratio of IgG subclasses as a predictive factor associated with treatment response of hydronephrosis in patients with iRPF.Methods:We retrospectively recruited 19 iRPF patients with hydronephrosis who evaluated serum IgG subclasses in a tertiary hospital between 2004 and 2019. Hydronephrosis was evaluated on the basis of imaging findings. Medications and clinical and laboratory findings, including IgG subclasses, were reviewed following the diagnosis of hydronephrosis. Hydronephrosis improvement on subsequent images was evaluated to assess treatment response. Categorised data were compared using chi-square or Fisher’s exact test. Continuous variables were compared using Mann–Whitney U test.Results:At baseline, median serum IgG3 and IgG4 levels were 64 (IQR 37–82) mg/dL and 71 (IQR 40–171) mg/dL. Five patients had serum IgG4 levels > 135 mg/dL and 11 patients had the reverse serum level of IgG4/IgG3. On subsequent images (median follow-up at 3.2 [IQR 1.7–4.0] months), 11 patients showed hydronephrosis improvement. The proportions of positive ratio of serum IgG4/IgG3 (81.8% vs. 25%, p = 0.024), periaortic involvement (81.8% vs. 25%, p = 0.024) and high-dose glucocorticoid treatment (45.5% vs. 0%, p = 0.045) were significantly higher in patients with improvement than in those without improvement (Table 1). Interestingly, even in cases with normal serum IgG4 levels, patients with improvement showed a higher serum IgG4/IgG3 ratio than in those without improvement (median 1.5 vs. 0.7, p = 0.038).Table 1.Clinical characteristics and treatment according to the shortterm outcome of hydronephrosisImprovement(n = 11)No improvement(n = 8)p-valueTime to subsequent imaging (months)a2.2 (1.3–4.2)3.2 (2.0–3.8)0.778Males (n, %)8 (72.7%)7 (87.5%)0.603Periaortic involvement (n, %)9 (81.8%)2 (25%)0.024Impaired renal function (n, %)b5 (45.5%)2 (25%)0.633Serum IgG4 (mg/dL)a114 (59–172)43 (35–109)0.152Elevated serum IgG4 (n, %)4 (36.4%)1 (12.5%)0.338Serum IgG4/IgG3 ratioa2.1 (1.2–4.9)0.8 (0.4–1.0)0.041Positive ratio of serum IgG4/IgG3 (n, %)9 (81.8%)2 (25%)0.024Medical treatment (n, %)7 (63.6%)1 (12.5%)0.059High-dose glucocorticoid treatment (n, %)5 (45.5%)0 (0%)0.045Surgical intervention (n, %)8 (72.7%)4 (50%)0.377aValues are median and interquartile range (25th–75thpercentile)bDefined as serum creatinine level > 1.24 mg/dLConclusion:The reverse ratio of serum IgG4/IgG3 was associated with hydronephrosis treatment response, thus suggesting favourable responses to high-dose corticosteroid.References:[1]Boonstra K, Culver EL, de Buy Wenniger LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology 2014;59:1954-63.Disclosure of Interests:None declared
Collapse
|
43
|
Choi SJ, Nam SH, Lee JS, Seo WJ, Oh JS, Hong S, Lee CK, Yoo B, Kim YG. FRI0088 CHANGE IN SERUM BILIRUBIN SUGGESTS TREATMENT RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH MOLECULAR-TARGETED AGENTS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Bilirubin is an antioxidant with anti-inflammatory properties. In previous reports, serum bilirubin levels were correlated with disease activity of autoimmune diseases including rheumatoid arthritis (RA). Various molecular-targeted agents have been developed for RA, and targets, such as IL-6 and TNFα, are associated with liver function. However, the association between serum bilirubin and treatment response in RA patients treated with molecular-targeted agents is still unknown.Objectives:We aimed to evaluate the role of serum bilirubin in the prediction of the early treatment response in RA patients who initiated molecular-targeted agents.Methods:We retrospectively recruited biologic naïve RA patients (n=292) with moderate-to-high disease activity from a tertiary hospital between Jan 2013 and Dec 2019. Patients with viral hepatitis, drug-induced hepatitis, or alcoholic liver disease were excluded. Molecular-targeted agents included tocilizumab (TCZ, n=40), adalimumab (ADA, n=59), etanercept (ETN, n=66), golimumab (GOL, n=60), abatacept (ABA, n=31), and tofacitinib (TOF, n=36). Clinical and laboratory data were collected from electronic medical records. Patients were categorised into an increased bilirubin group (higher serum bilirubin at 3 months than at baseline) and decreased bilirubin group (equal or lower serum bilirubin at 3 months than at baseline). At 6 months of treatment, good response (defined as a DAS28 score ≤3.2) was evaluated. Multivariate logistic regression analysis and multiple linear regression analysis were used to evaluate the association between serum bilirubin and treatment response. The variables included in the multiple logistic and linear regression analyses were age, female sex, rheumatoid factor, prednisolone, DMARDs, baseline liver enzymes, baseline DAS28 score, and components.Results:The mean serum bilirubin level at baseline was 4.7±1.8 mg/L. After 6 months of treatment, 180 (61.6%) patients achieved good responses. The mean serum bilirubin levels at 3 and 6 months were 5.3±2.3 and 5.5±2.2 mg/L, respectively. At 6 months, a good response was more frequent in the increased bilirubin group than in the decreased bilirubin group (71.2% [99/139] vs. 52.9% [81/153], p=0.001). In multivariate logistic regression analysis, the ORs among good responders at 6 months were 1.221 (95% CI 1.014–1.471, p=0.036) for baseline serum bilirubin and 1.377 (95% CI 1.146–1.654, p=0.001) for the change in serum bilirubin at 3 months. According to target agents, the mean changes in serum bilirubin from baseline to 6 months were 1.9±2.5 for TCZ, 1.0±1.5 for ADA, 0.7±1.9 for ETN, 0.6±2.2 for GOL, 0.3±1.2 for ABA, and 0.4±2.2 for TOF (Figure 1). Among the target agents, TCZ showed a significant increase in the mean serum bilirubin level at 3 and 6 months from baseline. In multiple linear regression analysis performed on TCZ, the change in bilirubin at 3 months was associated with the DAS28 score at 6 months (β=−0.349, p=0.020).Figure 1.Change in serum bilirubin during treatment with molecular-targeted agents in rheumatoid arthritis patientsConclusion:High baseline serum bilirubin and an increase in serum bilirubin during treatment are helpful to predict a good response to molecular-targeted agents, especially TCZ.Disclosure of Interests:None declared
Collapse
|
44
|
Lee JS, Nam SH, Choi SJ, Seo WJ, Hong S, Lee CK, Yoo B, Oh JS, Kim YG. FRI0248 PROGNOSTIC FACTORS FOR STEROID-FREE REMISSION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: IMPORTANCE OF ANTHROPOMETRIC MEASUREMENTS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Several studies have been conducted on factors associated with mortality in idiopathic inflammatory myopathies (IIM), but few studies have assessed prognostic factors for steroid-free remission in IIM.Objectives:We investigated the various clinical factors, including body measurements, that affect IIM treatment outcomes.Methods:Patients who were newly diagnosed with IIM between 2000 and 2018 were included. Steroid-free remission was defined as at least three months of normalisation of muscle enzymes and no detectable clinical disease activity. The factors associated with steroid-free remission were evaluated by a Cox regression analysis.Results:Of the 106 IIM patients, 35 displayed steroid-free remission during follow-up periods. In the multivariable Cox regression analyses, immunosuppressants’ early use within one month after diagnosis [hazard ratio (HR) 6.21, 95% confidence interval (CI) 2.61–14.74, p < 0.001] and sex-specific height quartiles (second and third quartiles versus first quartile, HR 3.65, 95% CI 1.40–9.51, p = 0.008 and HR 2.88, 95% CI 1.13–7.32, p = 0.027, respectively) were positively associated with steroid-free remission. Polymyositis versus dermatomyositis (HR 0.21, 95% CI 0.09–0.53, p = 0.001), presence of dysphagia (HR 0.15, CI 0.05–0.50, p = 0.002) and highest versus lowest quartile of waist circumference (WC) (HR 0.24, 95% CI 0.07–0.85, p = 0.027) were negatively associated with steroid-free remission.Conclusion:The early initiation of immunosuppressant therapy, type of myositis and presence of dysphagia are strong predictors of steroid-free remission in IIM; moreover, height and WC measurements at baseline may provide additional important prognostic value.Disclosure of Interests:None declared
Collapse
|
45
|
Ock HS, Hwang SW, Lee HJ, Kim CH, Kim SH, Kim TH, Lee JH, Lee JS. The effects of hidden female smokers on the association between smoking and chronic obstructive pulmonary disease in Korean adults. Pulmonology 2020; 27:286-295. [PMID: 32474057 DOI: 10.1016/j.pulmoe.2020.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Revised: 04/28/2020] [Accepted: 04/30/2020] [Indexed: 10/24/2022] Open
Abstract
OBJECTIVE Smoking is an important causative factor of chronic obstructive pulmonary disease (COPD), and females are considered more susceptible to the effects of smoking than males. However, in previous Korean studies, the effects of sex differences on the association between smoking and COPD have been controversial. In this study, the effects of sex differences on the association between smoking and COPD and the effects of female hidden smokers on that association in Korean adults were investigated. METHODS Data were acquired from the Korea National Health and Nutrition Examination Surveys (KNHANES). RESULTS The multivariate logistic regression analysis showed that self-reported smoking status for ex-smoker and current smoker correlated with COPD (odds ratio, OR: 1.67 and OR: 2.41, respectively). Self-reported smoking status for ex-smoker and current smoker correlated with COPD in men (OR: 1.61, OR: 2.43, respectively). Female self-reported current smoking status correlated with COPD (OR: 2.52), but female ex-smoker status was not significantly correlated with COPD. The ratios of cotinine-verified to self-reported smoking rates were 1.95 for women and 1.07 for men. CONCLUSION The results of this study were that sex differences might affect the association between COPD and smoking and that female hidden smoking might affect the association between smoking and COPD in Korean adults.
Collapse
Affiliation(s)
- H S Ock
- Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - S W Hwang
- Department of Thoracic and Cardiovascular Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - H J Lee
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - C H Kim
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - S H Kim
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - T H Kim
- Department of Pediatrics, Pusan National University, Pusan, Republic of Korea
| | - J H Lee
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
| | - J S Lee
- Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
| |
Collapse
|
46
|
Jahurul MHA, Nee SS, Norazlina MR, Hasmadi M, Sharifudin MS, Patricia M, Lee JS, Shihabul A, Amir HMS, Jumardi R, Noorakmar AW, Norliza J. Changes in microstructures of rambutan seed and the quality of its fat during drying. SN Appl Sci 2020. [DOI: 10.1007/s42452-020-2649-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
47
|
Yoon HM, Jo Y, Shim WH, Lee JS, Ko TS, Koo JH, Yum MS. Disrupted Functional and Structural Connectivity in Angelman Syndrome. AJNR Am J Neuroradiol 2020; 41:889-897. [PMID: 32381544 DOI: 10.3174/ajnr.a6531] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Accepted: 03/16/2020] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE This work investigated alterations in functional connectivity (FC) and associated structures in patients with Angelman syndrome (AS) by using integrated quantitative imaging analysis and connectivity measures. MATERIALS AND METHODS We obtained 3T brain MR imaging, including resting-state functional MR imaging, diffusion tensor imaging, and 3D T1-weighted imaging from children with AS (n = 14) and age- and sex-matched controls (n = 28). The brains of patients with AS were analyzed by measuring FC, white matter microstructural analysis, cortical thickness, and brain volumes; these were compared with brains of controls. RESULTS Interregional FC analysis revealed significantly reduced intra- and interhemispheric FC, especially in the basal ganglia and thalamus, in patients with AS. Significant reductions in fractional anisotropy were found in the corpus callosum, cingulum, posterior limb of the internal capsules, and arcuate fasciculus in patients with AS. Quantitative structural analysis also showed gray matter volume loss of the basal ganglia and diffuse WM volume reduction in AS compared with the control group. CONCLUSIONS This integrated quantitative MR imaging analysis demonstrated poor functional and structural connectivity, as well as brain volume reduction, in children with AS, which may explain the motor and language dysfunction observed in this well-characterized neurobehavioral phenotype.
Collapse
Affiliation(s)
- H M Yoon
- From the Department of Radiology and Research Institute of Radiology (H.M.Y., W.H.S., J.S.L., J.H.K.)
| | - Y Jo
- Asan Institute for Life Sciences (Y.J., W.H.S.), Asan Medical Center
| | - W H Shim
- From the Department of Radiology and Research Institute of Radiology (H.M.Y., W.H.S., J.S.L., J.H.K.)
- Asan Institute for Life Sciences (Y.J., W.H.S.), Asan Medical Center
| | - J S Lee
- From the Department of Radiology and Research Institute of Radiology (H.M.Y., W.H.S., J.S.L., J.H.K.)
| | - T S Ko
- Department of Pediatrics (T.S.K., M.S.Y.), Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea
| | - J H Koo
- From the Department of Radiology and Research Institute of Radiology (H.M.Y., W.H.S., J.S.L., J.H.K.)
| | - M S Yum
- Department of Pediatrics (T.S.K., M.S.Y.), Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
| |
Collapse
|
48
|
Ménard GC, Anselmetti GLR, Martinez EA, Puglia D, Malinowski FK, Lee JS, Choi S, Pendharkar M, Palmstrøm CJ, Flensberg K, Marcus CM, Casparis L, Higginbotham AP. Conductance-Matrix Symmetries of a Three-Terminal Hybrid Device. Phys Rev Lett 2020; 124:036802. [PMID: 32031865 DOI: 10.1103/physrevlett.124.036802] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Indexed: 06/10/2023]
Abstract
We present conductance-matrix measurements of a three-terminal superconductor-semiconductor hybrid device consisting of two normal leads and one superconducting lead. Using a symmetry decomposition of the conductance, we find that antisymmetric components of pairs of local and nonlocal conductances qualitatively match at energies below the superconducting gap, and we compare this finding with symmetry relations based on a noninteracting scattering matrix approach. Further, the local charge character of Andreev bound states is extracted from the symmetry-decomposed conductance data and is found to be similar at both ends of the device and tunable with gate voltage. Finally, we measure the conductance matrix as a function of magnetic field and identify correlated splittings in low-energy features, demonstrating how conductance-matrix measurements can complement traditional single-probe measurements in the search for Majorana zero modes.
Collapse
Affiliation(s)
- G C Ménard
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
- Microsoft Quantum-Copenhagen, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
| | - G L R Anselmetti
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
- Microsoft Quantum-Copenhagen, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
| | - E A Martinez
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
- Microsoft Quantum-Copenhagen, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
| | - D Puglia
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
- Microsoft Quantum-Copenhagen, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
| | - F K Malinowski
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
- Microsoft Quantum-Copenhagen, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
| | - J S Lee
- California NanoSystems Institute, University of California, Santa Barbara, California 93106, USA
| | - S Choi
- Department of Electrical Engineering, University of California, Santa Barbara, California 93106, USA
| | - M Pendharkar
- Department of Electrical Engineering, University of California, Santa Barbara, California 93106, USA
| | - C J Palmstrøm
- California NanoSystems Institute, University of California, Santa Barbara, California 93106, USA
- Department of Electrical Engineering, University of California, Santa Barbara, California 93106, USA
- Materials Department, University of California, Santa Barbara, California 93106, USA
| | - K Flensberg
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
| | - C M Marcus
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
- Microsoft Quantum-Copenhagen, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
| | - L Casparis
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
- Microsoft Quantum-Copenhagen, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
| | - A P Higginbotham
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
- Microsoft Quantum-Copenhagen, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
| |
Collapse
|
49
|
Lee JS, Cinanni N, Di Cristofaro N, Lee S, Dillenburg R, Adamo KB, Mondal T, Barrowman N, Shanmugam G, Timmons BW, Longmuir PW. Parents of Very Young Children with Congenital Heart Defects Report Good Quality of Life for Their Children and Families Regardless of Defect Severity. Pediatr Cardiol 2020; 41:46-53. [PMID: 31701166 DOI: 10.1007/s00246-019-02220-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Accepted: 10/15/2019] [Indexed: 10/25/2022]
Abstract
The purpose of this study was to investigate parent reports of quality of life for their very young children with congenital heart defects (CHD) and to compare their scores to previously published data. Parents of children 1-3 years old with CHD or innocent heart murmurs completed the Pediatric Quality of Life Inventory (PedsQL) core, cardiac, and family impact modules. Multivariable regression analyses assessed the impact of age, sex, family income, and CHD treatment history (study group) on PedsQL scores. Correlations between family impact and core/cardiac modules were examined. PedsQL scores were compared to healthy norms. 140 parents of young children participated within four study groups: CHD no treatment (n = 44), CHD treatment without bypass (n = 26), CHD treatment with bypass (n = 42) ,and innocent heart murmurs (n = 28). Male sex was associated with higher core (F = 4.16, p = 0.04, σ2 = .03) and cardiac quality of life (F = 4.41, p = .04, σ2 = 0.04). Higher family income was associated with higher family quality of life (F = 8.89, p < .01, σ2 = 0.13). Parents of children with innocent heart murmurs and children with CHD not requiring treatment had higher core quality of life compared to young healthy children. Cardiac-related quality of life scores were associated with family impact (r = 0.68) and core module (r = 0.63) quality of life scores. Parents of very young children with CHD report good quality of life for their children and families. Quality of life exceeds in children with innocent murmurs or CHD not requiring repair. Parents report a lower quality of life among girls, and lower family quality of life is associated with lower family income.
Collapse
Affiliation(s)
- J S Lee
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, RI#1-214, Ottawa, ON, K1H 8L1, Canada. .,Faculty of Health Science, University of Ottawa, Ottawa, Canada.
| | - N Cinanni
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, RI#1-214, Ottawa, ON, K1H 8L1, Canada
| | | | - S Lee
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, RI#1-214, Ottawa, ON, K1H 8L1, Canada.,Children's Hospital of Eastern Ontario, Ottawa, Canada
| | - R Dillenburg
- McMaster University, Hamilton, Canada.,McMaster Children's Hospital, Hamilton, Canada
| | - K B Adamo
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, RI#1-214, Ottawa, ON, K1H 8L1, Canada.,Faculty of Health Science, University of Ottawa, Ottawa, Canada
| | - T Mondal
- McMaster University, Hamilton, Canada.,McMaster Children's Hospital, Hamilton, Canada
| | - N Barrowman
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, RI#1-214, Ottawa, ON, K1H 8L1, Canada
| | - G Shanmugam
- Children's Hospital of Eastern Ontario, Ottawa, Canada
| | - B W Timmons
- McMaster University, Hamilton, Canada.,McMaster Children's Hospital, Hamilton, Canada
| | - P W Longmuir
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, RI#1-214, Ottawa, ON, K1H 8L1, Canada.,Faculty of Health Science, University of Ottawa, Ottawa, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, Canada
| |
Collapse
|
50
|
Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S. Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. Lupus 2019; 29:52-57. [DOI: 10.1177/0961203319890007] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Background Reduced renal function is associated with worse renal outcome in patients with lupus nephritis (LN). However, there is insufficient knowledge regarding renal function recovery in patients with LN with reduced baseline renal function. Therefore, the present study aimed to investigate renal function recovery and related factors in patients with reduced baseline renal function. Methods The present retrospective longitudinal cohort study included patients with LN and reduced renal function. Reduced renal function was defined as an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2. Recovery of renal function was determined by an eGFR of >60 mL/min/1.73 m2 at six months after baseline, and factors associated with it were evaluated using logistic regression analysis. Results We included 90 patients with LN, with a mean eGFR value of 37.2 ± 13.9 mL/min/1.73 m2. Forty-six (51.1%) patients recovered their renal function after six months. On multivariate analysis, hydroxychloroquine use (odds ratio (OR) = 3.891, 95% confidence interval (CI) 1.196–12.653, p = 0.024), prolonged LN (OR = 0.926, 95% CI 0.874–0.981, p = 0.009) and high-grade tubular atrophy (OR = 0.451, 95% CI 0.208–0.829, p = 0.013) were associated with renal function recovery. During follow up, 25 patients were on end-stage renal disease (ESRD). Kaplan–Meier analysis revealed that renal function recovery after six months and lower probability of ESRD are associated. Conclusions In patients with LN and reduced renal function, renal function recovery at six months was associated with use of hydroxychloroquine and inversely related to longer duration of LN and higher grade of tubular atrophy.
Collapse
Affiliation(s)
- J S Lee
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - J S Oh
- Department of Biomedical Informatics, Asan Medical Center, Seoul, Korea
| | - Y-G Kim
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - C-K Lee
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - B Yoo
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - S Hong
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| |
Collapse
|